

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Antimicrobial stewardship managed by clinical pharmacists reduced antibiotic use and drug resistance in a Chinese hospital, 2010–2016: a hospital population-based retrospective study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026072
Article Type:	Research
Date Submitted by the Author:	21-Aug-2018
Complete List of Authors:	Wang, Huaguang; Beijing Chaoyang Hospital, Wang, Han; School of Public Health, Peking University, Department of Maternal and Child Health Yu, Xiaojia; Beijing Chaoyang Hospital Zhou, Hong; Beijing Chaoyang Hospital Li, Boyu; Beijing Chaoyang Hospital Chen, Gang; Beijing Chaoyang Hospital Ye, Zhikang; Beijing Chaoyang Hospital Wang, Ying Cui, Xiangli; Beijing Chaoyang Hospital Zheng, Yunying; Beijing Chaoyang Hospital Zhao, Rui; Beijing Chaoyang Hospital Yang, Hui; Beijing Chaoyang Hospital Wang, Zihui; Beijing Chaoyang Hospital Wang, Peng; Beijing Chaoyang Hospital Yang, Chunxia; Beijing Chaoyang Hospital Liu, Lihong; Beijing Chaoyang Hospital,
Keywords:	antimicrobial stewardship, clinical pharmacist, antibiotic use, prophylactic antibiotic use, type-I incision operation, antimicrobial resistance

SCHOLARONE™  
Manuscripts

1  
2  
3 **Antimicrobial stewardship managed by clinical pharmacists reduced antibiotic use and**  
4 **drug resistance in a Chinese hospital, 2010–2016: a hospital population-based**  
5 **retrospective study**  
6  
7

8  
9 Huaguang Wang<sup>1</sup>, Han Wang<sup>2</sup>, Xiaojia Yu<sup>1</sup>, Hong Zhou<sup>1</sup>, Boyu Li<sup>1</sup>, Gang Chen<sup>1</sup>, Zhikang  
10 Ye<sup>1</sup>, Ying Wang<sup>1</sup>, Xiangli Cui<sup>1</sup>, Yunying Zheng<sup>1</sup>, Rui Zhao<sup>1</sup>, Hui Yang<sup>1</sup>, Zihui Wang<sup>1</sup>, Peng  
11 Wang<sup>3</sup>, Chunxia Yang<sup>3</sup>, Lihong Liu<sup>1\*</sup>  
12  
13

14  
15 <sup>1</sup> Huaguang Wang, <sup>1</sup> Xiaojia Yu, <sup>1</sup> Hong Zhou, <sup>1</sup> Boyu Li, <sup>1</sup> Gang Chen, <sup>1</sup> Zhikang Ye, <sup>1</sup>  
16 Xiangli Cui, <sup>1</sup> Ying Wang, <sup>1</sup> Yunying Zheng, <sup>1</sup> Rui Zhao, <sup>1</sup> Hui Yang, <sup>1</sup> Zihui Wang, <sup>1</sup>  
17 Lihong Liu : Department of Pharmacy, Beijing Chaoyang Hospital Affiliate of Capital  
18 University of Medical Sciences, Beijing, China  
19  
20

21  
22 <sup>2</sup> Han Wang : Department of Maternal and Child Health, School of Public Health, Peking  
23 University, Beijing, China  
24  
25

26  
27 <sup>3</sup> Peng Wang, <sup>3</sup> Chunxia Yang : Department of Infectious Diseases and Clinical Microbiology,  
28 Beijing Chaoyang Hospital Affiliate of Capital University of Medical Sciences, Beijing,  
29 China  
30  
31  
32  
33

34  
35 \*Corresponding author: [liulihong@bjcyh.com](mailto:liulihong@bjcyh.com) Tel: +86-10-85231788  
36

37  
38 Postal address: 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China, 100020  
39

40  
41 Word count: 3756  
42  
43

44 **ABSTRACT**  
45

46 **Objectives:** “National Special Stewardship in the Clinical Use of Antibiotics” was put  
47 forward in July, 2011 in China. We aimed to retrospectively analyze and evaluate impacts of  
48 antimicrobial stewardship (AMS) managed by clinical pharmacists on antibiotic utilization,  
49 prophylaxis, and antimicrobial resistance.  
50  
51  
52  
53

54  
55 **Design:** This was a retrospective observational study of trends in antibiotic use (2010–2016)  
56  
57

1  
2  
3 and antimicrobial resistance (2011–2016) in the context of AMS.

4  
5 **Setting:** Beijing Chaoyang Hospital, Affiliate of Capital University of Medical Sciences in  
6  
7 China, a 1400-bed tertiary hospital.

8  
9 **Data and participants:** Antibiotic prescriptions involving all outpatients and inpatients  
10  
11 during 2010–2016. Bacterial resistance data were from all inpatients during 2011–2016.

12  
13 **Interventions:** Multi-aspect intervention measures were implemented by clinical pharmacists,  
14  
15 such as formulating the activity program and performance management, advising on  
16  
17 antibacterial prescriptions, and training doctors.

18  
19 **Outcome measures:** The proportion of antibiotic prescriptions among outpatients and  
20  
21 inpatients, intensity of consumption (defined daily dose (DDD)/100 bed-days), antibiotic  
22  
23 prophylaxis in type I incision operations, and resistance rates of *Escherichia coli*, *Klebsiella*  
24  
25 *pneumoniae*, and *Pseudomonas aeruginosa* were retrospectively analyzed.

26  
27 **Results:** The proportion of antibiotic prescriptions decreased to 13.21% in outpatients and  
28  
29 34.65% in inpatients, and the intensity of consumption dropped to 37.38 DDD/100 bed-days.  
30  
31 The proportion of antibiotic prophylaxis was reduced to 18.93%. The proportion of rational  
32  
33 timing of the initial dose reached 96.74%, and the proportion of rational duration rose to  
34  
35 42.63%. Time series analysis demonstrated significant increases in the resistance rates of *E.*  
36  
37 *coli* and *K. pneumoniae* to carbapenems whereas the resistance rates of *E. coli* and *P.*  
38  
39 *aeruginosa* to fluoroquinolones decreased; the incidence rate of MRSA also decreased. The  
40  
41 intensity of consumption of antibiotics was partly positively correlated with changes in  
42  
43 resistance rate.

44  
45 **Conclusions:** Antimicrobial stewardship had an important role not in only reducing  
46  
47 antibiotics use and surgical antibiotic prophylaxis but also in reducing antimicrobial  
48  
49 resistance.

### Strengths and limitations of this study

- Our study described the entire process of AMS, from management of antibiotics use to monitoring of antimicrobial resistance, by demonstrating effective results and identifying existing problems.
- In this study, we aimed to demonstrate the correlation between antibiotics use (carbapenems and fluoroquinolones) and the antimicrobial resistance rate of common nosocomial pathogens (the three most frequently isolated bacteria in our hospital: *E. coli*, *K. pneumoniae*, and *P. aeruginosa* ).
- The findings of our study may indicate some potential directions for controlling the prevalence of CRE and MRSA.
- We compared our data with those of CHINET (the Chinese antimicrobial resistance surveillance network), which will help colleagues around the world to understand the current situation of bacterial resistance in China.
- Owing to space limitations, we did not discuss the economic changes of antibiotics use; this will be investigated in the future.

## INTRODUCTION

In 2004, the first Guidelines for the Clinical Use of Antibiotics (Guidelines for short) was issued by the National Health and Family Planning Commission (NHFPC, originally called the Ministry of Health) of the People's Republic of China, describing the characteristics of all types of antibiotics and how to properly use them in the treatment and prevention of infectious diseases; the Guidelines were updated in 2015. Regretfully, not all medical staff knew about the Guidelines or their significance. Today, antimicrobial resistance is one of the greatest threats to global health. There are four main factors contributing to the development and spread of antimicrobial resistance: inappropriate use of antibiotics in the

1  
2  
3 community and hospitals, misuse of antibiotics in the management of food-producing animals  
4 and in agriculture, and the presence of resistant bacteria in the environment. The former three  
5 factors could aggravate the last one.<sup>1</sup> Chinese data from the Ministry of Health National  
6 Antibacterial Resistance Surveillance Net (MOHNARIN) showed that antimicrobial  
7 resistance has been rising steadily each year.<sup>2</sup> Hospital pharmacists should improve the  
8 rational use of antibiotics as much as possible, to help in controlling antimicrobial resistance.  
9  
10  
11  
12  
13  
14  
15

16 On World Health Day 2011, the World Health Organization (WHO) began to take  
17 measures to combat the spread of antimicrobial resistance and strongly recommended  
18 governments to implement antimicrobial stewardship (AMS).<sup>3</sup> China acted immediately. In  
19 2011, the NHFPC of China put forward “National Special Stewardship in the Clinical Use of  
20 Antibiotics”,<sup>4</sup> the historically strictest management of antibiotics up to that date. The NHFPC  
21 set many goals for the use of clinical antibiotics, including restriction of antibiotic use in  
22 outpatients and inpatients and restricted antibiotic prophylactic use in clean operations, to  
23 promote rational antibiotics use and control antimicrobial resistance. These goals are  
24 described in detail below. This special stewardship policy mainly covered secondary and  
25 tertiary public hospitals and took effect on July 1, 2011. After that date, these hospitals were  
26 required to report data of antibiotics use to the government every month.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

40 In recent years, some studies have reported that AMS has had positive effects on  
41 controlling antibiotic-resistant pathogens, rational use of antibiotics, and cost savings,<sup>5</sup>  
42 <sup>6</sup>highlighting the importance of AMS. After many years of hard work, the status of antibiotics  
43 use has improved substantially at our hospital.  
44  
45  
46  
47

48 The aim of this study was to evaluate the effective impact of AMS on antibiotics use and  
49 antimicrobial resistance trends, to share our successful management experience, and to  
50 identify existing problems. To our knowledge, few studies<sup>7, 8</sup> have analyzed the correlation  
51 between antibiotics usage (defined daily dose, DDD) and multidrug-resistant organisms  
52  
53  
54  
55  
56  
57

(bacterial isolation rate), and these studies have mainly focused on critically ill patients, such as those in intensive care units. In this study, we sought to demonstrate the correlation between antibacterial usage and the antimicrobial resistance rate of common nosocomial pathogens, using data from all inpatients in our hospital.

## **METHODS**

### **Study design**

According to the requirements of the national policy, “Special Stewardship in the Clinical Use of Antibiotics” was a 3-year plan (2011–2013). In April of 2014, the NHFPC issued a Notice Regarding Implementing Stewardship of Antibacterial Use in the Clinic,<sup>9</sup> its aim was to continuously maintain the positive effects gained during the previous 3 years. Accordingly, in our retrospective study, phases were divided into three stages, as follows. Stage 1: baseline phase (July 2010 to June 2011); stage 2: intervention phase (July 2011 to December 2013); and stage 3: stability phase (January 2014 to December 2016).

### **Patient and public involvement**

The patients were not involved or recruited in this study. The Ethics Committee of Beijing Chaoyang Hospital agreed exemption applications of informed consent. The antibiotics utilization data was extracted directly from the Hospital Information System (HIS) and electronic medical records of all hospitalized patients (2010-2016). The bacterial resistance data from all inpatients (2011-2016) was provided by the Department of Infectious Diseases and Clinical Microbiology.

### **Ethics statement**

This study was approved by the Ethics Committee of Beijing Chaoyang Hospital Affiliate of Capital University of Medical Sciences.

### **Multi-aspect intervention measures**

### **Organization construction**

To implement the program “National Special Stewardship in the Clinical Use of Antibiotics”, an AMS group was set up in our hospital, which was attached to the Drug and Therapeutics Committee (DTC). The AMS group was composed of administrators, clinicians, infectious disease physicians, pharmacists, microbiologists, and information staff, and included a leadership group and expert group. The leadership group was responsible for work deployment and supervision whereas the expert group was responsible for technical guidance, training doctors on rational use of antibiotics, carrying out all tasks of AMS, and so on. As expected, the medical department led AMS in many hospitals in China, but in our hospital, the pharmacy department was the leading department, for the following reasons. (1) The pharmacy department in our hospital was not only a technical section but also a functional section. The pharmacy director was responsible for medication use. (2) There were many clinical pharmacists, such as infectious disease pharmacists who had sufficient knowledge and clinical experience to manage AMS. (3) The clinical pharmacists were working in the clinical departments every day, so they could give their professional advice regarding antibiotics use directly to doctors.

### **Formulating the activity program and administrative intervention**

The AMS group formulated the activity program of stewardship and some regulations on antibiotic use were issued, as follows. (1) Antibiotic classification management system. All antibiotics were classified as non-restricted, restricted, and special grade antibiotics. Physicians with different professional titles were matched to the corresponding grade of antibiotic prescribing privileges. (2) Management system of antibiotic prescribing privileges. In May of 2012, the Regulations on Clinical Applications of Antibiotics were issued by the NHFPC, which took effect on August, 1, 2012. These were the first valid regulations on antibiotics in China.<sup>10</sup> The Regulations required that physicians would not be given antibiotic



prescribing privileges until they passed an exam, after completing training in the use of antibiotics. This prescribing privilege restriction was embedded into the Hospital Information System (HIS). (3) Regulation of perioperative prophylactic antibiotics use in clean operations, in which the choice of antibiotics, dose, timing of the initial dose, and duration of antibiotic prophylaxis were described.

According to the requirements of the national antibiotic stewardship program,<sup>4</sup> the AMS group established the goals for antibiotic application in the hospital (Table 1).

**Table 1** Goals of clinical antibiotic use established by the NHFPC in 2011

Antibiotic outcome measures	Goals
1. Proportion of inpatients receiving antibiotics	≤ 60%
2. Proportion of outpatients receiving antibiotics	≤ 20%
3. Intensity of inpatients' antibiotic consumption	≤ 40 DDD/100 bed-days
4. Proportion of antibiotic prophylaxis in patients receiving type I incision operations/clean operations	≤ 30%
5. Timing of initial dose of preoperative antibiotic prophylaxis	Within 0.5–2 h before surgical incision
6. Duration of antibiotic prophylaxis in patients receiving type I incision operations/clean operations	Within 24 h after the end of operation

### Performance management

Every year, the directors of clinical departments were asked by the director of the hospital to sign responsibility agreements for antibiotic use. Hospital leaders and the pharmacy director, together with clinical pharmacists, established or updated the performance appraisal system for antibiotic use, which indicated the circumstances to be rewarded or punished. For example, if clinical departments did not accomplish their goals, the directors would be fined 1000–3000 RMB, and doctors would be fined 300–500 RMB. If the clinical

1  
2  
3 departments accomplished their goals, the directors would be rewarded with 1000–5000  
4 RMB and doctors with 300–1000 RMB, which were greater than the amounts of fines.

### 7 **Antibiotic prescription evaluation and training**

9 Retrospective rationality evaluation of antibiotic prescriptions for outpatients,  
10 emergency room patients, and inpatients was performed monthly by clinical pharmacists.  
11 Irrational prescriptions would be flagged in the Antibacterial Monitoring Report published by  
12 the pharmacy department each month; this report was made available to all medical staff.  
13 According to the frequency and severity of irrational prescriptions, some doctors would be  
14 fined.  
15  
16  
17  
18  
19  
20  
21

22 Clinical pharmacists were responsible for training the medical staff on rational use of  
23 antibiotics. If necessary, pharmacists would go to the clinical departments to give lectures.  
24  
25

### 26 **Multiple cooperation**

27  
28 Antibiotics data monitoring could not be implemented without the support of the  
29 information department. At the start of AMS at our hospital, data extraction modules were  
30 embedded into the HIS after discussions between clinical pharmacists and information  
31 personnel. Later, an automatic prescription screening system was also included in the HIS,  
32 which could intercept irrational prescriptions, such as repeated use or unreasonable  
33 combinations. Furthermore, clinical pharmacists took part in the Core Expert Meeting of  
34 Antibacterial Application held by the Infection Management Office, to discuss usage  
35 problems with carbapenems and glycopeptides. If irrational use was confirmed by the experts,  
36 the relevant physician would be penalized 1–2 points (1 point corresponded to a 100 RMB  
37 fine).  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 **Data collection and outcome measures**

51  
52  
53 Antibiotic outcome measures are shown in Table 1 (see “Antibiotic outcome measures”).  
54  
55 The antibiotic utilization data was collected directly from the HIS. Antibiotic consumption  
56

was standardized according to the Anatomical Therapeutic Chemical (ATC) classification system and the DDD was used as a measuring unit, as recommended by the WHO Collaborating Center for Drug Statistics Methodology.<sup>11</sup> The intensity of inpatients' antibiotic consumption was expressed as DDD per 100 bed-days. Information of type I incision operations was extracted from patients' electronic medical records. The outcome measures of antimicrobial resistance included the resistance rates of *Escherichia coli*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa* and incidence rate of methicillin-resistant *Staphylococcus aureus* (MRSA) in our hospital. The bacteriological data were obtained from the clinical microbiology laboratory. We analyzed the correlation between antibiotic consumption and antimicrobial resistance.

## Statistical analysis

Segmented regression analysis of interrupted time series was used to analyze the monthly data of antibiotic utilization, which were divided into three stages (the baseline phase, intervention phase, and stability phase), to illustrate the effect of AMS. The statistical model in this study was as follows.<sup>12</sup>

$$Y_t = \beta_0 + \beta_1 \times \text{time}_t + \beta_2 \times \text{intervention}_t + \beta_3 \times \text{time after intervention}_t + \beta_4 \times \text{stability}_t + \beta_5 \times \text{time after stability}_t + e_t$$

In this model,  $Y_t$  was the average monthly value of the outcome measure at month  $t$ ;  $\beta_0$  estimates the level change in the outcome during the baseline phase;  $\beta_1$  estimates the trend change during the baseline phase;  $\beta_2$  estimates the level change during the intervention phase;  $\beta_3$  estimates the trend change during the intervention phase;  $\beta_4$  estimates the level change during the stability phase; and  $\beta_5$  estimates the trend change during the stability phase. The parameter level was the value of a time series at the beginning of a given time series; the parameter trend was the rate of change in an outcome measure; *time* was a

1  
2  
3 continuous variable indicating time in months at time  $t$  starting from the baseline phase (time  
4 0); *intervention* was an indicator for time  $t$  occurring before ( $intervention = 0$ ) or after  
5 ( $intervention = 1$ ) the multi-aspect intervention, which started at month 13 (July 2011); *time*  
6 *after intervention* was a continuous variable counting the months after the intervention;  
7 *stability* was an indicator for time  $t$  occurring before ( $stability = 0$ ) or after stability ( $stability$   
8  $= 1$ ), which started at month 43 (January 2014); *time after stability* was a continuous variable  
9 counting the months after stability. The error term,  $e_t$ , represented variation unexplained by  
10 the segmented regression model.  
11  
12  
13  
14  
15  
16  
17  
18

19  
20 Comparisons of the average monthly values of outcome measures for antibiotic use  
21 during the three phases were conducted using the Bonferroni test. Box charts were plotted for  
22 data visualization, with error bars representing standard deviations.  
23  
24  
25

26  
27 In addition, a time series analysis model (autoregressive integrated moving average,  
28 ARIMA)<sup>8</sup> was used to analyze the trends in annual antibiotic use, antimicrobial resistance  
29 trends, and incidence trend of MRSA from 2011 to 2016. The  $\beta$  value indicated the variation  
30 of dependent variables when independent variables changed one unit at uniform time  
31 intervals. Pearson correlation coefficients were used to examine the relationships between  
32 antimicrobial resistance, the incidence rate of MRSA, and antibiotic use.  
33  
34  
35  
36  
37  
38

39  
40 All statistics were performed using SAS, version 9.3 (SAS Institute, Cary, NC, USA).  
41 All reported  $P$  values were two-sided, with  $P < 0.05$  considered statistically significant.  
42  
43  
44  
45

## 46 RESULTS

### 47 Change trends in antibiotics utilization rate and intensity

48  
49 Changes in the proportion of antibiotic prescriptions in outpatients and inpatients during  
50 the baseline, intervention, and stability phases are shown in Figure 1A, 1B, 1C and 1D. The  
51 associated parameters of time series analysis are summarized in Table 2. The proportion of  
52  
53  
54  
55  
56  
57

antibiotic prescriptions in outpatients and inpatients declined by 0.33% ( $P < 0.05$ ) and by 0.59% ( $P < 0.05$ ) each month during the intervention stage, respectively. Bonferroni tests (Figure 1B) showed that the proportion of antibiotic prescriptions in outpatients was reduced from 19.38% during the baseline phase to 13.21% during the stability phase ( $P < 0.05$ ). The proportion of antibiotic prescriptions among inpatients decreased significantly from 64.34% during the baseline phase to 34.65% during the stability phase ( $P < 0.05$ ) (Figure 1D). Figure 1E and Table 2 showed that the intensity of inpatient antibiotic consumption decreased significantly by 6.46 DDD/100 bed-days ( $P < 0.001$ ) per month during the first year of the intervention stage. Figure 1F showed the intensity of consumption dropped from the baseline phase to the stability phase (102.46 vs. 37.38 DDD/100 bed-days;  $P < 0.05$ ). All the outcomes mentioned above met the national standards. In the stability phase, the  $\beta 5$  value for the intensity of consumption (0.70;  $P < 0.001$ ) implied a gradually increasing trend; this still met national standards.

**Table 2** Time series analysis of change trends in antibiotic utilization

Antibiotic measures	outcome	$\beta 1$ -trend (baseline)	$\beta 2$ -level (intervention)	$\beta 3$ -trend (intervention)	$\beta 4$ -level (stability)	$\beta 5$ -trend (stability)
Proportion-O		-0.01 (0.04)	0.55 (0.83)	-0.33 (0.12)*	0.48 (0.85)	-0.19 (0.14)
Proportion-I		-0.25 (0.10)*	-5.03 (2.22)*	-0.59 (0.29)*	3.61 (2.23)	-0.66 (0.74)
Intensity-I		-0.04 (0.04)	-7.44 (3.62)*	-6.46 (0.56)***	4.20 (1.45)**	0.70 (0.19)***
Proportion-type I		-0.10 (0.04)*	-7.26 (2.92)*	-5.71 (0.61)***	-0.18 (1.44)	-0.12 (0.12)
Timing-type I		-0.01 (0.07)	0.64 (1.72)	1.18 (0.59)*	1.63 (2.00)	-0.17 (0.24)
Duration-type I		0.28 (0.06)***	8.78 (2.15)**	0.10 (0.27)	5.35 (1.44)***	-1.19 (0.19)***

Outcomes of antibiotic utilization included proportion of antibiotic prescriptions in outpatients (Proportion-O), inpatients (Proportion-I), and intensity of consumption in inpatients (Intensity-I).

Outcomes of antibiotic prophylaxis included proportion of prophylaxis (Proportion-type I), proportion of

1  
2  
3 rational timing (Timing-type I), and proportion of rational duration (Duration-type I). Parameters of  $\beta 1$ – $\beta 5$   
4 were expressed as mean (SE), which represented the changes in level and trend.

5  
6 \* $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ .  
7  
8  
9

## 10 **Change trends of antibiotic prophylaxis in type I incision operations**

11  
12  
13 The proportion of antibiotic prophylaxis in patients undergoing type I incision  
14 operations was significantly reduced by 5.71% ( $P < 0.001$ ) monthly during the first year of  
15 the intervention phase (Figure 2A, Table 2), decreasing from 98.94% during the baseline  
16 phase to 18.93% during the stability phase ( $P < 0.05$ ) (Figure 2B). The proportion of rational  
17 timing of the initial dose increased by 1.18% ( $P < 0.05$ ) each month during the intervention  
18 stage (Figure 2C, Table 2), also increasing from 71.11% during the baseline phase to 96.74%  
19 during the stability phase ( $P < 0.05$ ) (Figure 2D). These two outcomes all eventually reached  
20 national standards. Although the proportion of rational duration of antibiotic prophylaxis  
21 showed an increasing trend during the intervention phase (0.10;  $P < 0.05$ ), the difference was  
22 not statistically significant (Figure 2E, Table 2). However, in the stability phase, this showed  
23 a decreasing trend (–1.19;  $P < 0.001$ ), which did not meet the national standard ( $\geq 90\%$ ).  
24 Figure 2F showed the proportion of rational duration, increasing from 2.84% during the  
25 baseline phase to 42.63% during the stability phase ( $P < 0.05$ ).  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

## 44 **Trends in resistance rates for common gram-negative bacilli and** 45 **incidence rate of MRSA, 2011–2016**

46  
47  
48 Time series analysis demonstrated a significant increase in the resistance rates of *E.*  
49 *coli* to carbapenems during 2011–2016 ( $P < 0.05$ ). The  $\beta$  value indicated that the resistance  
50 rates of *E. coli* to imipenem and meropenem increased by 0.27% and 0.22% each year,  
51 respectively. However, the resistance rates of *E. coli* to levofloxacin and ciprofloxacin  
52  
53  
54  
55  
56  
57  
58  
59  
60

significantly decreased by 1.62% and 1.40% each year, respectively ( $P < 0.01$  and  $P < 0.001$ ) (Table 3).

**Table 3** Trend changes in antimicrobial resistance of *E.coli* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate (%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	0	0	0.1	0.4	0.5	1.5	Increasing	0.2657	0.0239
Meropenem	0	0	0	0.3	0.3	1.3	Increasing	0.2200	0.0471
Levofloxacin	61.3	61.3	59.1	57.7	55.5	53.9	Decreasing	-1.6191	0.0013
Ciprofloxacin	64.3	64.3	61.2	61.4	58.7	58.2	Decreasing	-1.4038	0.0002

Time series analysis demonstrated a significant increase in the resistance rates of *K. pneumoniae* to carbapenems ( $P < 0.05$ ). The  $\beta$  value indicated that the resistance rates of *K. pneumoniae* to imipenem and meropenem increased by 1.29% and 1.14% each year, respectively. The resistance rates of *K. pneumoniae* to fluoroquinolones (FQs) remained stable (Table 4).

**Table 4** Trend changes in antimicrobial resistance of *K. pneumoniae* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate (%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	2.0	1.5	1	4.8	7.1	6.9	Increasing	1.2937	0.049
Meropenem	1.8	1.5	1	4.1	6.2	6.4	Increasing	1.1381	0.047
Levofloxacin	27.9	27.9	18.4	12.9	14.6	15.2	Stable	-3.0218	0.0973
Ciprofloxacin	28.9	28.9	20.2	15.5	17.0	19.0	Stable	-2.4467	0.1643

Time series analysis showed a significant decrease in the resistance rates of *P.*

*aeruginosa* to FQs ( $P < 0.05$  and  $P < 0.01$ ). The  $\beta$  value indicated that the resistance rate of *P. aeruginosa* to levofloxacin and ciprofloxacin decreased by 4.78% and 2.27% each year, respectively. Resistance rates of *P. aeruginosa* to carbapenems remained stable (Table 5).

**Table 5** Trend changes in antimicrobial resistance of *P. aeruginosa* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate (%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	23.1	20.9	15.2	16.5	15.3	15.8	Stable	-1.4811	0.1008
Meropenem	18.2	16.2	10.1	12.9	11.4	11.4	Stable	-1.2977	0.1140
Levofloxacin	28.1	28.1	20.5	10.0	10.1	8.1	Decreasing	-4.7833	0.0137
Ciprofloxacin	18.2	18.2	13.5	11.6	10.5	7.5	Decreasing	-2.2677	0.0011

Our study shows that the incidence rate of nosocomial MRSA decreased significantly by 5.26% each year, declining from 68.0% (2011) to 37.5% (2016) ( $P < 0.001$ ) (Supplementary Table S1).

## Correlation between antibiotic consumption and antimicrobial resistance

Because carbapenems and FQs are often used for nosocomial infection, we focused on evaluating the impact of use of these drugs on antimicrobial resistance. We found that the intensity of consumption of imipenem/cilastatin significantly increased from 0.59 to 1.36 DDD/100 bed-days ( $P < 0.01$ ). However, the intensity of consumption of FQs significantly decreased each year ( $P < 0.01$  and  $P < 0.05$ ), respectively (Supplementary Table S2).

Increased consumption of imipenem/cilastatin was correlated with the prevalence of imipenem-resistant *E. coli*, ( $r = 0.8651$ ,  $P < 0.05$ ). Similarly, decreased consumption of FQs



was associated with the decreased resistance rate of *E. coli* to levofloxacin and ciprofloxacin ( $r = 0.8954$  and  $r = 0.8950$ , respectively;  $P < 0.05$ ) (Table 6).

**Table 6** Correlation between antibiotic intensity of consumption and resistance rates of *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and incidence rate of MRSA

Antibiotics	<i>E. coli</i>		<i>K. pneumoniae</i>		<i>P. aeruginosa</i>		MRSA	
	r	p	r	p	r	p	r	p
Imipenem/cilastatin	0.8651	0.0261	0.9050	0.0131	-0.7477	0.0875	-0.9611	0.0022
Meropenem	0.3252	0.5295	0.4095	0.4201	0.3672	0.4739	0.0012	0.9982
Levofloxacin	0.8954	0.0158	0.7523	0.0844	0.8954	0.0159	0.9450	0.0045
Ciprofloxacin	0.8950	0.0160	0.9209	0.0091	0.9282	0.0075	0.8883	0.0180

Antibiotics refer to intensity of consumption (DDD/100 bed-days); bacteria (*E. coli*, *K. pneumoniae*, and *P. aeruginosa*) refer to their resistance rates (%) to antibiotics; MRSA refers to incidence rate of MRSA (%).  
r: correlation coefficient.

There was a relationship between the increased resistance rate of *K. pneumoniae* to imipenem/cilastatin and increased intensity of consumption of imipenem/cilastatin ( $r = 0.9050$ ,  $P < 0.05$ ). Although time series analysis showed a stable trend in the resistance rate of *K. pneumoniae* to ciprofloxacin (Table 4), there was still a significantly positive correlation between the prevalence of ciprofloxacin-resistant *K. pneumoniae* and use of ciprofloxacin ( $r = 0.9209$ ,  $P < 0.01$ ) (Table 6).

Table 6 indicates that the resistance rate of *P. aeruginosa* to FQs was correlated with the consumption of FQs ( $r = 0.8954$ ,  $P < 0.05$  for levofloxacin and  $r = 0.9282$ ,  $P < 0.01$  for ciprofloxacin).

The incidence rate of MRSA was positively correlated with the consumption of FQs ( $r = 0.9450$ ,  $P < 0.01$  for levofloxacin and  $r = 0.8883$ ,  $P < 0.05$  for ciprofloxacin). However, we found that the incidence rate of MRSA was negatively correlated with the consumption of

1  
2  
3 imipenem/cilastatin ( $r = -0.9611$ ,  $P < 0.01$ ) (Table 6).  
4  
5

## 6 7 **DISCUSSION** 8

9  
10 The global mortality attributable to antimicrobial resistance is estimated to reach 10  
11 million annually by 2050, which would make it one of the leading causes of death, with an  
12 economic impact of up to 100 trillion US dollars (USD).<sup>13</sup> Therefore, many countries  
13 worldwide have implemented AMS, with many achieving positive effects in the rational use  
14 of antibiotics and health care cost savings.<sup>14-18</sup>  
15  
16  
17  
18  
19

20 The implementation of AMS in our hospital is managed by clinical pharmacists and  
21 supported by the DTC. After many years of AMS, the proportion of antibiotic prescriptions  
22 decreased to 13.21% among outpatients and 34.65% among inpatients. The intensity of  
23 antibiotic consumption was reduced to 37.38 DDD/100 bed-days. These outcomes are similar  
24 to the study by Bao *et al.*<sup>10</sup> Regarding antibiotic prophylaxis in type I incision operations, the  
25 proportion of antibiotic prophylaxis decreased to 18.93% and the proportion of rational  
26 timing of the initial dose increased to 96.74%. Only the proportion of rational duration of  
27 antibiotic prophylaxis (42.63%) did not reach the national standard, for the following reasons.  
28  
29 First, coronary artery bypass graft (CABG) surgery belongs to type I incision operations,  
30 according to the Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,<sup>19</sup> the  
31 duration of prophylaxis for cardiothoracic procedures is up to 48 hours, with no supporting  
32 evidence. Chinese Guidelines suggest prophylactic duration be no more than 48 hours. But  
33 CABG involves important viscera, in which the consequences of infection would be severe.  
34  
35 Therefore, doctors hesitate to stop antibiotics within 48 hours after surgery. Second, in  
36 orthopedic surgeries, such as open reduction and plate or screw internal fixation of fractures  
37 in consideration of implants, doctors also hesitate to stop antibiotics within 24 hours after  
38 surgery. Third, the difficult doctor-patient relationships in China make physicians hesitant  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 about premature discontinuation of antibiotics.

4  
5 The aim of AMS is to limit the prevalence of antimicrobial resistance. The results  
6  
7 showed that with decreased intensity of FQ consumption, the resistance rates of *E. coli* and *P.*  
8  
9 *aeruginosa* to FQs and incidence rate of MRSA showed decreasing trends, and they were  
10  
11 positively correlated. This implies that controlling the use of FQs might limit the prevalence  
12  
13 of antimicrobial resistance as well as limit the emergence of MRSA; the latter is consistent  
14  
15 with previous studies.<sup>20,21</sup> Other studies<sup>22-25</sup> have reported that a reduction in  
16  
17 second/third-generation cephalosporins and clindamycin contributes to a reduction in both  
18  
19 incidence rate of MRSA and prevalence density of MRSA bacteremia. In our study, we also  
20  
21 found that the incidence rate of MRSA was negatively correlated with imipenem/cilastatin  
22  
23 use, which was difficult to explain. To our knowledge, few studies have obtained results  
24  
25 similar to ours. Lai *et al.* reported<sup>26</sup> a significant correlation between increased use of  
26  
27 linezolid and teicoplanin and decreased prevalence of MRSA. Therefore, we theorize that the  
28  
29 reduced use of non-special grade antibiotics (such as FQs and others) leads to a compensatory  
30  
31 increased use of carbapenems; however, this negative correlation requires further exploration.  
32  
33 In addition, we found the resistance rate of *E. coli* and *K. pneumoniae* to carbapenems  
34  
35 showed an increasing trend, meaning that carbapenem-resistant Enterobacteriaceae (CRE)  
36  
37 could pose a serious threat. On March 3, 2017, the NHFPC issued a Notice Regarding Further  
38  
39 Reinforcement in Management of Clinical Application of Antibacterial to Control Bacteria  
40  
41 Resistance, which required medical institutions to gather, archive, and analyze patient  
42  
43 information with respect to the use of carbapenems, to help control the prevalence of CRE.<sup>27</sup>

44  
45  
46  
47  
48 CHINET surveillance of antimicrobial resistance in China reported the resistance trends  
49  
50 from 2005 to 2014, using data from 19 hospitals.<sup>28</sup> In our hospital, the resistance rates of *E.*  
51  
52 *coli*, *K. pneumoniae*, and *P. aeruginosa* to imipenem/cilastatin and meropenem in 2014 (0.4%  
53  
54 and 0.9%, 4.8% and 4.1%, 16.5% and 12.9%, respectively) were significantly lower than  
55  
56

1  
2  
3 those reported by CHINET (0.9% and 1.0%, 10.5% and 13.4%, 26.6% and 24.3%,  
4 respectively). This proved that AMS in our hospital played an important role in the control of  
5 antimicrobial resistance.  
6  
7

8  
9 Some limitations of this study should be noted. First, this study only represented the  
10 experience of a single medical institution. Second, because AMS has been ongoing for many  
11 years, several different clinical pharmacists have successively participated in the evaluation  
12 of prophylactic antibiotic use; therefore, the evaluation results might be affected slightly by  
13 individual differences.  
14  
15  
16  
17  
18

## 19 20 21 22 **CONCLUSION**

23  
24 This study demonstrated that AMS managed by clinical pharmacists has an important  
25 role in reducing and optimizing antibiotic use and controlling antimicrobial resistance. The  
26 findings of our study indicate some directions to pursue in controlling the prevalence of CRE  
27 and MRSA. Antimicrobial resistance is rising worldwide, so continual effort regarding AMS  
28 is critical not only in large hospitals but also in primary or community hospitals.  
29  
30  
31  
32  
33  
34  
35  
36  
37

38 **Acknowledgments** The authors thank Guosheng Feng and Zhaohui Tong, directors of  
39 Beijing Chaoyang Hospital, for supporting and promoting antimicrobial stewardship work.  
40 We also thank Analisa Avila, ELS, of Liwen Bianji, Edanz Group China  
41 ([www.liwenbianji.cn/ac](http://www.liwenbianji.cn/ac)), for editing the English text of a draft of this manuscript.  
42  
43  
44  
45

46 **Contributors** LHL was the leader of AMS and responsible for supervising the work, work  
47 plan, and manuscript review. HGW was responsible for carrying out AMS and collecting,  
48 analyzing, and reporting data; she wrote this manuscript and made some amendments after  
49 review. HW was responsible for statistical analysis and wrote the analysis method in the  
50 manuscript. XJY, HZ, BYL, GC, ZKY, YW, XLC, YYZ, RZ, ZHW, HY were all involved in  
51  
52  
53  
54  
55  
56  
57

1  
2  
3 the different aspects of data collection. PW and CXY provided the bacterial resistance data.

4  
5 All authors were involved in data verification.

6  
7 **Funding** There is no specific funding for this study.

8  
9 **Competing interests** None declared.

10  
11 **Patient consent** Not required.

12  
13 **Ethics approval** Beijing Chaoyang Hospital Ethics Committee.

14  
15 **Data sharing statement** We state that if our manuscript is accepted and published, we  
16  
17 would be pleased to share our data with readers to improve the rational use of antibiotics.

## 18 19 20 **REFERENCES**

- 21  
22 1. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog Glob*  
23  
24 *Health* 2015;109(7):309-18.
- 25  
26 2. Xiao YH, Giske CG, Wei ZQ, *et al.* Epidemiology and characteristics of antimicrobial resistance in China. *Drug*  
27  
28 *Resist Updat* 2011;14(4-5):236-50.
- 29  
30 3. World Health Organization. Global strategy for containment of antimicrobial resistance.  
31  
32 2010. [http://www.who.int/csr/resources/publications/drugresist/en/EGlobal\\_Stratpdf](http://www.who.int/csr/resources/publications/drugresist/en/EGlobal_Stratpdf)
- 33  
34 4. National Health and Family Planning Commission of the People's Republic of China. Notice regarding  
35  
36 National Special Measure Scheme on Clinical Use of Antibiotics[in Chinese].2011.  
37  
38 <http://www.nhfpc.gov.cn/zwgkzt/wsbyysj/201104/51376.shtml>
- 39  
40 5. Zhang HX, Li X, Huo HQ, *et al.* Pharmacist interventions for prophylactic antibiotic use in urological inpatients  
41  
42 undergoing clean or clean-contaminated operations in a Chinese hospital. *PLoS One* 2014;9(2):e88971.
- 43  
44 6. Davey P, Brown E, Charani E, *et al.* Interventions to improve antibiotic prescribing practices for hospital  
45  
46 inpatients. *Cochrane Database Syst Rev* 2013;(4):CD003543.
- 47  
48 7. Ma X, Xie J, Yang Y, *et al.* Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant  
49  
50 organism isolates in critically ill patients: a pre-post study from a single center. *BMC Infect Dis*  
51  
52 2016;16(1):704.
- 53  
54 8. Xu J, Duan X, Wu H, *et al.* Surveillance and correlation of antimicrobial usage and resistance of *Pseudomonas*  
55  
56 *aeruginosa*: a hospital population-based study. *PLoS One* 2013;8(11):e78604.

- 1  
2  
3 9. Notice Regarding Implementing Stewardship of Antibacterial Use in Clinic in April 2014 [in  
4 Chinese]. 2014. <http://www.nhfpc.gov.cn/zyygj/s3593/201404/49973560ddde4293a489b158081d777c.shtml>
- 5  
6  
7 10. National Health and Family Planning Commission of the People's Republic of China. Regulations on Clinical  
8 Applications of Antibiotics [in Chinese]. 2012.  
9  
10 <http://www.nhfpc.gov.cn/zyygj/s3593/201205/e5efd852b86c4afa8b09a0e58e09e10e.shtml>
- 11  
12 11. World Health Organization. Collaborating Center for Drug Statistics Methodology: Guidelines for ATC  
13 classification and DDD assignment 2017.  
14  
15 [http://www.who.cn/filearchive/publications/2017\\_guidelines\\_webpdf](http://www.who.cn/filearchive/publications/2017_guidelines_webpdf).
- 16  
17 12. Bao L, Peng R, Wang Y, *et al*. Significant reduction of antibiotic consumption and patients' costs after an  
18 action plan in China, 2010-2014. *PLoS One* 2015;10(3):e0118868.
- 19  
20 13. Alawi MM, Darwesh BM. A stepwise introduction of a successful antimicrobial stewardship program.  
21 Experience from a tertiary care university hospital in Western, Saudi Arabia. *Saudi Med J*  
22 2016;37(12):1350-1358.
- 23  
24 14. Song P, Li W, Zhou Q. An outpatient antibacterial stewardship intervention during the journey to JCI  
25 accreditation. *BMC Pharmacol Toxicol* 2014;15:8.
- 26  
27 15. Dinh A, Duran C, Davido B, *et al*. Impact of an antimicrobial stewardship program to optimize antimicrobial  
28 use for outpatients at emergency department. *J Hosp Infect* 2017 Jul 8. pii: S0195-6701(17)30387-0.
- 29  
30 16. Doernberg SB, Dudas V, Trivedi KK. Implementation of an antimicrobial stewardship program targeting  
31 residents with urinary tract infections in three community long-term care facilities: a quasi-experimental  
32 study using time-series analysis. *Antimicrob Resist Infect Control* 2015;4:54.
- 33  
34 17. Jenkins TC, Knepper BC, Shihadeh K, *et al*. Long-term outcomes of an antimicrobial stewardship program  
35 implemented in a hospital with low baseline antibiotic use. *Infect Control Hosp Epidemiol*  
36 2015;36(6):664-72.
- 37  
38 18. Li Z, Cheng B, Zhang K, *et al*. Pharmacist-driven antimicrobial stewardship in intensive care units in East  
39 China: A multicenter prospective cohort study. *Am J Infect Control* 2017;45(9):983-9.
- 40  
41 19. Bratzler DW, Dellinger EP, Olsen KM, *et al*. Clinical practice guidelines for antimicrobial prophylaxis in  
42 surgery. *Am J Health Syst Pharm* 2013;70(3):195-283.
- 43  
44 20. Charbonneau P, Parienti JJ, Thibon P, *et al*. Fluoroquinolone use and methicillin-resistant *Staphylococcus*  
45 *aureus* isolation rates in hospitalized patients: a quasi experimental study. *Clin Infect Dis* 2006;42(6):778-84.

- 1  
2  
3 21. Weber SG, Gold HS, Hooper DC, *et al.* Fluoroquinolones and the risk for methicillin-resistant *Staphylococcus*  
4 *aureus* in hospitalized patients. *Emerg Infect Dis* 2003;9(11):1415-22.  
5  
6 22. Aldeyab MA, Scott MG, Kearney MP, *et al.* Impact of an enhanced antibiotic stewardship on reducing  
7 methicillin-resistant *Staphylococcus aureus* in primary and secondary healthcare settings. *Epidemiol Infect*  
8 2014;142(3):494-500.  
9  
10 23. Lawes T, Edwards B, Lopez-Lozano JM, *et al.* Trends in *Staphylococcus aureus* bacteraemia and impacts of  
11 infection control practices including universal MRSA admission screening in a hospital in Scotland,  
12 2006-2010: retrospective cohort study and time-series intervention analysis. *BMJ Open* 2012;2(3).  
13  
14 24. Tacconelli E, De Angelis G, Cataldo MA, *et al.* Does antibiotic exposure increase the risk of  
15 methicillin-resistant *Staphylococcus aureus* (MRSA) isolation? A systematic review and meta-analysis. *J*  
16 *Antimicrob Chemother* 2008;61(1):26-38.  
17  
18 25. Borde JP, Kaier K, Steib-Bauert M, *et al.* Feasibility and impact of an intensified antibiotic stewardship  
19 programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center.  
20 *BMC Infect Dis* 2014;14:201.  
21  
22 26. Lai CC, Chu CC, Cheng A, *et al.* Correlation between antimicrobial consumption and incidence of  
23 health-care-associated infections due to methicillin-resistant *Staphylococcus aureus* and  
24 vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010. *J Microbiol Immunol*  
25 *Infect* 2015;48(4):431-6.  
26  
27 27. National Health and Family Planning Commission ( NHFPC ) of the People's Republic of China. Notice  
28 regarding Further reinforcement the Management of Clinical Application of Antibacterial to Control  
29 Bacteria Resistant [in Chinese].2017.  
30 <http://www.nhfpc.gov.cn/yzygj/s7659/201703/d2f580480cef4ab1b976542b550f36cf.shtml>.  
31  
32 28. Hu FP, Guo Y, Zhu DM, *et al.* Resistance trends among clinical isolates in China reported from CHINET  
33 surveillance of bacterial resistance, 2005-2014. *Clin Microbiol Infect* 2016;22 Suppl 1:S9-14.  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

## Figure legends:

52  
53  
54 **Figure 1. Changes in proportion of antibiotic prescriptions and intensity of**  
55  
56

**consumption.**

Time series curves of each monthly value of antibiotic prescribing proportions, plotted for outpatients (A) and inpatients (C). Each monthly value of intensity of antibiotic consumption was plotted for inpatients (E). The Bonferroni test was conducted to compare these data in three stages, for antibiotic prescribing proportion among outpatients (B) and inpatients (D), and intensity of antibiotic consumption (F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.

**Figure 2. Changes in antibiotic prophylaxis in type I incision operations.**

Time series curves of each monthly value of antibiotic prophylaxis were plotted for proportion of prophylaxis (A), proportion of rational timing (C), and proportion of rational duration (E). These data in three stages were compared by Bonferroni test (B, D, and F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.






Figure 1. Changes in proportion of antibiotic prescriptions and intensity of consumption.

Time series curves of each monthly value of antibiotic prescribing proportions, plotted for outpatients (A) and inpatients (C). Each monthly value of intensity of antibiotic consumption was plotted for inpatients (E).

The Bonferroni test was conducted to compare these data in three stages, for antibiotic prescribing proportion among outpatients (B) and inpatients (D), and intensity of antibiotic consumption (F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.

388x207mm (144 x 144 DPI)




Figure 2. Changes in antibiotic prophylaxis in type I incision operations. Time series curves of each monthly value of antibiotic prophylaxis were plotted for proportion of prophylaxis (A), proportion of rational timing (C), and proportion of rational duration (E). These data in three stages were compared by Bonferroni test (B, D, and F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.

546x292mm (144 x 144 DPI)

## Supplementary materials

**Table S1** Trend changes in incidence rate of methicillin-resistant *Staphylococcus aureus* from 2011 to 2016

	By year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	<i>P</i>
<b>Incidence rate (%)</b>	68.0	60.3	58.3	49.8	51.5	37.5	Decreasing	-5.2565	0.0007

**Table S2** Usage trend changes of carbapenems and fluoroquinolones from 2011 to 2016

Anti biotic	Anti biotic consumption (DDD/100 bed-days) by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	<i>P</i>
Imipenem/cilastatin	0.59	0.71	0.79	1.17	1.16	1.36	Increasing	0.1599	0.0013
Meropenem	0.86	0.34	0.29	0.38	0.66	0.69	Stable	-0.0116	0.9193
Levofloxacin	11.18	9.70	10.64	7.74	7.71	6.35	Decreasing	-0.9292	0.0033
Ciprofloxacin	6.17	4.12	2.49	0.91	0.66	0.45	Decreasing	-1.1811	0.0461

DDD, defined daily dose.

## STROBE Statement—checklist of items that should be included in reports of observational studies

**Our research met all the items of STROBE statement.**

	Item No	Recommendation	Page number
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-5
Objectives	3	State specific objectives, including any prespecified hypotheses	3-5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2,4,5,8,9
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Not Applicable for this study.
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	1,2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	8-10
		(c) Explain how missing data were addressed	None
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	Not Applicable for this study
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy			
	(e) Describe any sensitivity analyses	8-10	

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Continued on next page

For peer review only

<b>Results</b>		<b>Page number</b>	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	2-3
		(b) Give reasons for non-participation at each stage	Applicable for this study
		(c) Consider use of a flow diagram	Applicable for this study
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Applicable for this study
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Applicable for this study
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Applicable for this study
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	19-21
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	4,22
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-22
Generalisability	21	Discuss the generalisability (external validity) of the study results	20-22
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	None

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use and drug resistance in a Chinese hospital, 2010–2016: a retrospective observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026072.R1
Article Type:	Research
Date Submitted by the Author:	11-Mar-2019
Complete List of Authors:	Wang, Huaguang; Beijing Chaoyang Hospital, Wang, Han; School of Public Health, Peking University, Department of Maternal and Child Health Yu, Xiaojia; Beijing Chaoyang Hospital Zhou, Hong; Beijing Chaoyang Hospital Li, Boyu; Beijing Chaoyang Hospital Chen, Gang; Beijing Chaoyang Hospital Ye, Zhikang; Beijing Chaoyang Hospital Wang, Ying Cui, Xiangli; Beijing Chaoyang Hospital Zheng, Yunying; Beijing Chaoyang Hospital Zhao, Rui; Beijing Chaoyang Hospital Yang, Hui; Beijing Chaoyang Hospital Wang, Zihui; Beijing Chaoyang Hospital Wang, Peng; Beijing Chaoyang Hospital Yang, Chunxia; Beijing Chaoyang Hospital Liu, Lihong; Beijing Chaoyang Hospital,
<b>Primary Subject Heading</b>:	Medical management
Secondary Subject Heading:	Infectious diseases, Pharmacology and therapeutics, Public health
Keywords:	antimicrobial stewardship, clinical pharmacist, antibiotic use, prophylactic antibiotic use, type-I incision operation, antimicrobial resistance

SCHOLARONE™  
Manuscripts

1  
2  
3 **Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use**  
4 **and drug resistance in a Chinese hospital, 2010–2016: a retrospective observational**  
5 **study**  
6  
7  
8  
9

10 Huaguang Wang<sup>1</sup>, Han Wang<sup>2</sup>, Xiaojia Yu<sup>1</sup>, Hong Zhou<sup>1</sup>, Boyu Li<sup>1</sup>, Gang Chen<sup>1</sup>, Zhikang  
11 Ye<sup>1</sup>, Ying Wang<sup>1</sup>, Xiangli Cui<sup>1</sup>, Yunying Zheng<sup>1</sup>, Rui Zhao<sup>1</sup>, Hui Yang<sup>1</sup>, Zihui Wang<sup>1</sup>, Peng  
12 Wang<sup>3</sup>, Chunxia Yang<sup>3</sup>, Lihong Liu<sup>1\*</sup>  
13  
14

15  
16  
17 <sup>1</sup> Huaguang Wang, <sup>1</sup> Xiaojia Yu, <sup>1</sup> Hong Zhou, <sup>1</sup> Boyu Li, <sup>1</sup> Gang Chen, <sup>1</sup> Zhikang Ye, <sup>1</sup>  
18 Xiangli Cui, <sup>1</sup> Ying Wang, <sup>1</sup> Yunying Zheng, <sup>1</sup> Rui Zhao, <sup>1</sup> Hui Yang, <sup>1</sup> Zihui Wang, <sup>1</sup> Lihong  
19 Liu : Department of Pharmacy, Beijing Chaoyang Hospital Affiliate of Capital University of  
20 Medical Sciences, Beijing, China  
21  
22  
23

24  
25  
26 <sup>2</sup> Han Wang: Department of Maternal and Child Health, School of Public Health, Peking  
27 University, Beijing, China  
28  
29

30  
31 <sup>3</sup> Peng Wang, <sup>3</sup> Chunxia Yang: Department of Infectious Diseases and Clinical Microbiology,  
32 Beijing Chaoyang Hospital Affiliate of Capital University of Medical Sciences, Beijing,  
33 China  
34  
35  
36

37 \*Corresponding author: [liulihong@bjcyh.com](mailto:liulihong@bjcyh.com) Tel: +86-10-85231788

38  
39  
40 Postal address: 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China, 100020

41  
42 Word count: 4121  
43  
44  
45  
46

## 47 **ABSTRACT**

48  
49 **Objectives:** “National Special Stewardship in the Clinical Use of Antibiotics” was put  
50 forward in July, 2011 in China. We aimed to retrospectively evaluate the impact of  
51 antimicrobial stewardship (AMS) managed by clinical pharmacists on antibiotic utilization,  
52 prophylaxis and antimicrobial resistance (AMR).  
53  
54  
55  
56  
57

58  
59 **Design:** This was a retrospective observational study of trends in antibiotic use and AMR in  
60



1  
2  
3 the context of AMS.  
4

5 **Setting:** Beijing Chaoyang Hospital, a 1400-bed tertiary hospital, in China.  
6

7 **Data and participants:** Antibiotic prescriptions from 820 doctors included all outpatients  
8 (N=17766637) and inpatients (N=376627) during 2010–2016. Bacterial resistance data were  
9  
10 from all inpatients (N=350699) during 2011–2016.  
11  
12

13 **Interventions:** Multi-aspect intervention measures were implemented by clinical pharmacists  
14 (13persons), e.g. formulating the activity program and performance management, advising on  
15  
16 antibacterial prescriptions and training.  
17  
18

19 **Outcome measures:** The proportion of antibiotic prescriptions among outpatients and  
20  
21 inpatients, intensity of consumption in defined daily dose (DDD)/100 bed-days, antibiotic  
22  
23 prophylaxis in type I incision operations, and resistance rates of *Escherichia coli*, *Klebsiella*  
24  
25 *pneumoniae*, and *Pseudomonas aeruginosa* were retrospectively analyzed.  
26  
27  
28

29 **Results:** The proportion of antibiotic prescriptions decreased in outpatients (from 19.38% to  
30  
31 13.21%) and in inpatients (from 64.34% to 34.65%), the intensity of consumption dropped  
32  
33 from 102.46 to 37.38 DDD/100 bed-days. The proportion of antibiotic prophylaxis decreased  
34  
35 from 98.94% to 18.93%. The proportion of rational timing of initial dose increased from  
36  
37 71.11% to 96.74%, the proportion of rational duration rose from 2.84% to 42.63%. Time  
38  
39 series analysis demonstrated the resistance rates of *E. coli* and *P. aeruginosa* to  
40  
41 fluoroquinolones decreased, the incidence rate of methicillin-resistant *Staphylococcus aureus*  
42  
43 (MRSA) also decreased; whereas the resistance rates of *E. coli* and *K. pneumoniae* to  
44  
45 carbapenems increased. The antibiotic use was partly positively correlated with AMR.  
46  
47  
48  
49

50 **Conclusions:** AMS had an important role in reducing antibiotic use and surgical antibiotic  
51  
52 prophylaxis. The AMR was positively correlated with antibiotic consumption to some extent.  
53  
54  
55

56  
57  
58 **Strengths and limitations of this study**  
59  
60

- 1
- 2
- 3 ■ Our study described the entire process of AMS, from management of antibiotic use to
- 4 AMR monitoring.
- 5
- 6
- 7
- 8 ■ Time series analysis, a better tool, was applied to analyze the change trends in antibiotic
- 9 utilization and AMR.
- 10
- 11
- 12 ■ By exploring the correlation between antibiotic use and AMR, this study may indicate
- 13 some potential directions for controlling the prevalence of CRE and MRSA.
- 14
- 15
- 16
- 17 ■ This was a retrospective observational study without simultaneous control group, the bias
- 18 couldn't be well controlled; the evaluation of prophylactic antibiotic use by different
- 19 clinical pharmacists might have individual differences.
- 20
- 21
- 22
- 23
- 24
- 25
- 26

## 27 INTRODUCTION

28

29 In 2004, the first Guidelines for the Clinical Use of Antibiotics (Guidelines for short)

30 was issued by the National Health and Family Planning Commission (NHFPC, originally

31 called the Ministry of Health) of the People's Republic of China, describing the

32 characteristics of all types of antibiotics and appropriate use in treatment and prevention of

33 infectious diseases; the Guidelines were updated in 2015. Regretfully, not all medical staff

34 knew about the Guidelines or their significance. Today, antimicrobial resistance (AMR) is

35 one of the greatest threats to global health. There are four main factors contributing to the

36 spread of AMR: inappropriate use of antibiotics in the community and in hospitals, misuse of

37 antibiotics in animal production and agriculture, and the presence of resistant bacteria in the

38 environment. The former three factors could aggravate the last one.<sup>1</sup> Chinese data from the

39 Ministry of Health National Antibacterial Resistance Surveillance Net (MOHNARIN)

40 showed that AMR has been rising steadily each year.<sup>2</sup>

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 In 2001 the World Health Organization (WHO) began to take measures to combat the

58 spread of AMR and strongly recommended governments to implement antimicrobial

59

60

1  
2  
3 stewardship (AMS).<sup>3</sup>On World Health Day 2011, AMR was also selected as the theme. In  
4  
5 response to AMR, in 2011 the NHFPC of China put forward “National Special Stewardship  
6  
7 in the Clinical Use of Antibiotics”,<sup>4</sup> the historically strictest management of antibiotics up to  
8  
9 that date. The NHFPC set many goals for the clinical use of antibiotics, including restriction  
10  
11 of antibiotic use in outpatients and inpatients and restriction of antibiotic prophylactic use in  
12  
13 clean operations, to promote rational antibiotic use and control AMR. These goals are  
14  
15 described in detail below. This special stewardship policy mainly covered secondary and  
16  
17 tertiary public hospitals and took effect on July 1, 2011. After that date, these hospitals were  
18  
19 required to report data of antibiotic use to the government every month.  
20  
21  
22

23  
24 In recent years, some studies have reported that AMS had positive effects on controlling  
25  
26 antibiotic-resistant pathogens, rational use of antibiotics, and cost savings,<sup>5,6</sup> highlighting the  
27  
28 importance of AMS. There were also some studies<sup>7-11</sup> that analyzed the correlation between  
29  
30 antibiotic use and AMR, although these all demonstrated the effectiveness of AMS, but the  
31  
32 studied population, antibiotic and pathogen are different, and the results of correlation  
33  
34 between antibiotic use and AMR were not exactly the same.  
35  
36

37  
38 The aim of this study was to evaluate the impact of AMS on antibiotic use and AMR  
39  
40 trends, to share our successful management experience, and to identify existing problems. In  
41  
42 addition, because the doctors' prescription behaviors and antibiotic variety are different in  
43  
44 each country or region, so is the status of AMR, therefore we sought to demonstrate the  
45  
46 correlation between antibiotic use and antimicrobial resistance rate of common nosocomial  
47  
48 pathogens, using data from all inpatients in our hospital.  
49  
50

## 51 **METHODS**

### 52 **Study design**

53  
54  
55 According to the requirements of the national policy, “Special Stewardship in the  
56  
57 Clinical Use of Antibiotics” was a 3-year plan (2011–2013). In April of 2014, the NHFPC  
58  
59

1  
2  
3 issued a Notice Regarding Implementing Stewardship of Antibacterial Use in the Clinic;<sup>12</sup>its  
4  
5 aim was to continuously maintain the positive effects gained during the previous 3 years.  
6  
7 Accordingly, in our retrospective study, phases were divided into three stages, as follows.  
8  
9 Stage 1: baseline phase (July 2010 to June 2011); stage 2: intervention phase (July 2011 to  
10  
11 December 2013); and stage 3: stability phase (January 2014 to December 2016).  
12  
13  
14

## 15 **Patient and public involvement**

16  
17 The antibiotic utilization data was extracted directly from the Hospital Information  
18  
19 System (HIS) and electronic medical records of all patients (2010-2016). The patient's  
20  
21 personal information was hidden. The bacterial resistance data from all inpatients (2011-2016)  
22  
23 was provided by the Department of Infectious Diseases and Clinical Microbiology. Clinical  
24  
25 sample sources included blood, cerebrospinal fluid, pleural effusion, ascites, urine and  
26  
27 sputum, etc. Duplicate isolates, defined as the isolates of the same species that showed the  
28  
29 same susceptibility results at the same site for each patient in different days, were excluded,  
30  
31 only the first isolated strain was included in the study (excluding isolates of surveillance  
32  
33 cultures).  
34  
35  
36  
37

## 38 **Ethics statement**

39  
40 This study was approved by the Ethics Committee of Beijing Chaoyang Hospital  
41  
42 (Approval Number: 2017-11-28-3). Because the patient's privacy was not violated in the  
43  
44 study, so the Ethics Committee agreed exemption applications of informed consent.  
45  
46  
47

## 48 **Multi-aspect intervention measures**

### 49 **Organization construction**

50  
51 To implement the program “National Special Stewardship in the Clinical Use of  
52  
53 Antibiotics”, an AMS group was set up in our hospital, which was attached to the Drug and  
54  
55 Therapeutics Committee (DTC). The AMS group was composed of administrators, clinicians,  
56  
57 infectious disease physicians, pharmacists, microbiologists, and information staff, and  
58  
59  
60

1  
2  
3 included a leadership group and expert group. The leadership group was responsible for work  
4 deployment and supervision whereas the expert group was responsible for technical guidance,  
5  
6 participation in consultations, training doctors on rational use of antibiotics and  
7  
8 implementation of AMS monitoring (such as data collection and report, prescription review  
9  
10 and feedback, AMR monitoring, etc). Generally the medical department led AMS in many  
11  
12 hospitals in China, but in our hospital, the pharmacy department was the leading department,  
13  
14 for the following reasons. (1) The pharmacy department in our hospital is not only a technical  
15  
16 section but also a functional section. The pharmacy director is responsible for medication use.  
17  
18 (2) There are many clinical pharmacists, such as infectious disease pharmacists who have  
19  
20 sufficient knowledge and clinical experience to manage AMS. (3) Clinical pharmacists work  
21  
22 in the clinical departments every day, so they could give their professional advice regarding  
23  
24 antibiotic use directly to doctors.  
25  
26  
27  
28  
29

### 30 **Formulating the activity program and administrative intervention**

31  
32  
33 The AMS group formulated the activity program of stewardship and some regulations  
34 on antibiotic use were issued, as follows. (1) Antibiotic classification management system.  
35  
36 All antibiotics were classified as non-restricted, restricted, and special grade antibiotics.  
37  
38 Physicians with different professional titles were matched to the corresponding grade of  
39  
40 antibiotic prescribing privileges. (2) Management system of antibiotic prescribing privileges.  
41  
42 In May of 2012, the Regulations on Clinical Applications of Antibiotics were issued by the  
43  
44 NHFPC, which took effect on August, 1, 2012. These were the first valid regulations on  
45  
46 antibiotics in China.<sup>13</sup>The regulations required that physicians would not be given antibiotic  
47  
48 prescribing privileges until they passed an exam, after completing training on rational use of  
49  
50 antibiotics. This prescribing privilege restriction was embedded into the Hospital Information  
51  
52 System (HIS). (3) Regulation of perioperative prophylactic antibiotic use in clean operations,  
53  
54 in which the choice of antibiotics, dose, timing of the initial dose, and duration of antibiotic  
55  
56  
57  
58  
59  
60

prophylaxis were described.

According to the requirements of the national antibiotic stewardship program,<sup>4</sup> the AMS group established the goals for antibiotic application in the hospital (Table 1).

**Table 1** Goals of clinical antibiotic use established by the NHFPC in 2011

Antibiotic outcome measures	Goals
1. Proportion of inpatients receiving antibiotics	≤ 60%
2. Proportion of outpatients receiving antibiotics	≤ 20%
3. Intensity of inpatients' antibiotic consumption	≤ 40 DDD/100 bed-days
4. Proportion of antibiotic prophylaxis in patients receiving type I incision operations/clean operations	≤ 30%
5. Timing of initial dose of preoperative antibiotic prophylaxis	Within 0.5–2 h before surgical incision
6. Duration of antibiotic prophylaxis in patients receiving type I incision operations/clean operations	Within 24 h after the end of operation

### Performance management

Every year, the directors of clinical departments were asked by the director of the hospital to sign responsibility agreements for antibiotic use. Hospital leaders and the pharmacy director, together with clinical pharmacists, established or updated the performance appraisal system for antibiotic use, which indicated the circumstances to be rewarded or penalized. For example, if clinical departments did not accomplish their goals, the directors would be fined 1000–3000CNY, and doctors would be fined 300–500CNY. If the clinical departments accomplished their goals, the directors would be rewarded with 1000–5000 CNY and doctors with 300–1000 CNY, which were greater than the amounts of fines.

### Antibiotic prescription evaluation and training

Retrospective rationality evaluation of antibiotic prescriptions for outpatients,

1  
2  
3 emergency room patients, and inpatients was performed monthly by clinical pharmacists. For  
4  
5 example, some doctors used moxifloxacin to treat urinary tract infections, which didn't  
6  
7 conform to the recommendation of guideline and medicine specification; the combination of  
8  
9 imipenem/cilastatin and metronidazole was unsuitable, the latter was unnecessary. Clinical  
10  
11 pharmacists would contact the doctors to modify the prescriptions. Inappropriate  
12  
13 prescriptions would be flagged in the Antibacterial Monitoring Report published by the  
14  
15 pharmacy department each month; this report was made available to all medical staff.  
16  
17 According to the frequency and severity of inappropriate prescriptions, some doctors would  
18  
19 be fined.  
20  
21  
22

23  
24 Clinical pharmacists were responsible for training the medical staff on rational use of  
25  
26 antibiotics. Training was conducted every 6 months in two forms. (1) Clinical pharmacists  
27  
28 gave lessons to the medical staff in the lecture hall, they need to complete an exam after class.  
29  
30 (2) Clinical pharmacists and the medical department jointly made online learning and exam,  
31  
32 medical staff was required to finish it. If necessary, pharmacists would go to the clinical  
33  
34 departments to give lectures.  
35  
36

### 37 **Multiple cooperation**

38  
39  
40 Antibiotics data monitoring could not be implemented without the support of the  
41  
42 information department. At the start of AMS at our hospital, data extraction modules were  
43  
44 embedded into the HIS after discussions between clinical pharmacists and information  
45  
46 personnel. Later, an automatic prescription screening system was also included in the HIS,  
47  
48 which could intercept inappropriate prescriptions, such as repeated use or unreasonable  
49  
50 combinations. Furthermore, clinical pharmacists took part in the Core Expert Meeting of  
51  
52 Antibacterial Application held by the Infection Management Office, to discuss usage  
53  
54 problems with carbapenems and glycopeptides. If inappropriate use was confirmed by the  
55  
56 experts, the relevant physician would be penalized 100–200CNY fine.  
57  
58  
59  
60

## Data collection and outcome measures

Antibiotic outcome measures are shown in Table 1 (see “Antibiotic outcome measures”). The antibiotic utilization data was collected directly from the HIS. Antibiotic consumption was standardized according to the Anatomical Therapeutic Chemical (ATC) classification system and the DDD was used as a measuring unit, as recommended by the WHO Collaborating Center for Drug Statistics Methodology.<sup>14</sup> The intensity of inpatients’ antibiotic consumption was expressed as DDD per 100 bed-days. Information of type I incision operations was extracted from inpatients’ electronic medical records. The outcome measures of AMR included the resistance rates of *Escherichia coli*, *Klebsiella pneumonia*, and *Pseudomonas aeruginosa* and incidence rate of methicillin-resistant *Staphylococcus aureus* (MRSA) in our hospital. The bacteriological data were obtained from the clinical microbiology laboratory. We analyzed the correlation between antibiotic consumption and AMR.

## Statistical analysis

Segmented regression analysis of interrupted time series was used to analyze the monthly data of antibiotic utilization, which were divided into three stages (the baseline phase, intervention phase, and stability phase), to illustrate the effect of AMS. The statistical model in this study was as follows.<sup>15</sup>

$$Y_t = \beta_0 + \beta_1 \times \text{time}_t + \beta_2 \times \text{intervention}_t + \beta_3 \times \text{time after intervention}_t + \beta_4 \times \text{stability}_t + \beta_5 \times \text{time after stability}_t + e_t$$

In this model,  $Y_t$  was the average monthly value of the outcome measure at month  $t$ ;  $\beta_0$  estimates the level change in the outcome during the baseline phase;  $\beta_1$  estimates the trend change during the baseline phase;  $\beta_2$  estimates the level change during the intervention phase;  $\beta_3$  estimates the trend change during the intervention phase;  $\beta_4$  estimates the level



1  
2  
3 change during the stability phase; and  $\beta_5$  estimates the trend change during the stability phase.  
4  
5 The parameter level was the value of a time series at the beginning of a given time series; the  
6  
7 parameter trend was the rate of change in an outcome measure; *time* was a continuous  
8  
9 variable indicating time in months at time *t* starting from the baseline phase (time 0);  
10  
11 *intervention* was an indicator for time *t* occurring before (*intervention*=0) or after  
12  
13 (*intervention*=1) the multi-aspect intervention, which started at month 13 (July 2011); *time*  
14  
15 *after intervention* was a continuous variable counting the months after the intervention;  
16  
17 *stability* was an indicator for time *t* occurring before (*stability*=0) or after stability  
18  
19 (*stability*=1), which started at month 43 (January 2014); *time after stability* was a continuous  
20  
21 variable counting the months after stability. The error term,  $e_t$ , represented variation  
22  
23 unexplained by the segmented regression model.  
24  
25  
26  
27  
28

29 Comparisons of the average monthly values of outcome measures for antibiotic use  
30  
31 during the three phases were conducted using the Bonferroni test. Box charts were plotted for  
32  
33 data visualization, with error bars representing standard deviations.  
34  
35

36 In addition, a time series analysis model (autoregressive integrated moving average,  
37  
38 ARIMA)<sup>8</sup> was used to analyze the trends in annual antibiotic use, AMR trends, and incidence  
39  
40 trend of MRSA from 2011 to 2016. The  $\beta$  value indicated the variation of dependent  
41  
42 variables when independent variables changed one unit at uniform time intervals. Pearson  
43  
44 correlation coefficients were used to examine the relationships between antimicrobial  
45  
46 resistance rate, the incidence rate of MRSA, and antibiotic use.  
47  
48

49 All statistics were performed using SAS, version 9.3 (SAS Institute, Cary, NC, USA).  
50  
51 All reported *P* values were two-sided, with  $P < 0.05$  considered statistically significant.  
52  
53  
54  
55

## 56 RESULTS

### 57 Change trends in antibiotic utilization rate and intensity

Changes in the proportion of antibiotic prescriptions in outpatients and inpatients during the baseline, intervention, and stability phases are shown in Figure 1A, 1B, 1C and 1D. The associated parameters of time series analysis are summarized in Table 2. The proportion of antibiotic prescriptions in outpatients and inpatients declined by 0.33% ( $P < 0.05$ ) and by 0.59% ( $P < 0.05$ ) each month during the intervention stage, respectively. Bonferroni tests (Figure 1B) showed that the proportion of antibiotic prescriptions in outpatients was reduced from 19.38% during the baseline phase to 13.21% during the stability phase ( $P < 0.05$ ). The proportion of antibiotic prescriptions among inpatients decreased significantly from 64.34% during the baseline phase to 34.65% during the stability phase ( $P < 0.05$ ) (Figure 1D). Figure 1E and Table 2 showed that the intensity of inpatients' antibiotic consumption decreased significantly by 6.46 DDD/100 bed-days ( $P < 0.001$ ) per month during the first year of the intervention stage. Figure 1F showed the intensity of consumption dropped from the baseline phase to the stability phase (102.46 vs. 37.38 DDD/100 bed-days;  $P < 0.05$ ). All the outcomes mentioned above met the national standards. In the stability phase, the  $\beta 5$  value for the intensity of consumption (0.70;  $P < 0.001$ ) implied a gradually increasing trend; this still met national standards.

**Table 2** Time series analysis of change trends in antibiotic utilization

Antibiotic outcome measures	$\beta 1$ -trend (baseline)	$\beta 2$ -level (intervention)	$\beta 3$ -trend (intervention)	$\beta 4$ -level (stability)	$\beta 5$ -trend (stability)
Proportion-O	-0.01 (0.04)	0.55 (0.83)	-0.33 (0.12)*	0.48 (0.85)	-0.19 (0.14)
Proportion-I	-0.25 (0.10)*	-5.03 (2.22)*	-0.59 (0.29)*	3.61 (2.23)	-0.66 (0.74)
Intensity-I	-0.04 (0.04)	-7.44 (3.62)*	-6.46 (0.56)***	4.20 (1.45)**	0.70 (0.19)***
Proportion-type I	-0.10 (0.04)*	-7.26 (2.92)*	-5.71 (0.61)***	-0.18 (1.44)	-0.12 (0.12)
Timing-type I	-0.01 (0.07)	0.64 (1.72)	1.18 (0.59)*	1.63 (2.00)	-0.17 (0.24)

Duration-type I	0.28 (0.06)***	8.78 (2.15)**	0.10 (0.27)	5.35 (1.44)***	-1.19 (0.19)***
-----------------	----------------	---------------	-------------	----------------	-----------------

Outcomes of antibiotic utilization included proportion of antibiotic prescriptions in outpatients (Proportion-O), inpatients (Proportion-I), and intensity of consumption in inpatients (Intensity-I). Outcomes of antibiotic prophylaxis included proportion of prophylaxis (Proportion-type I), proportion of rational timing (Timing-type I), and proportion of rational duration (Duration-type I). Parameters of  $\beta_1$ – $\beta_5$  were expressed as mean (SE), which represented the changes in level and trend.

\* $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ .

### Change trends of antibiotic prophylaxis in type I incision operations

The proportion of antibiotic prophylaxis in patients undergoing type I incision operations was significantly reduced by 5.71% ( $P < 0.001$ ) monthly during the first year of the intervention phase (Figure 2A, Table 2), decreasing from 98.94% during the baseline phase to 18.93% during the stability phase ( $P < 0.05$ ) (Figure 2B). The proportion of rational timing of the initial dose increased by 1.18% ( $P < 0.05$ ) each month during the intervention stage (Figure 2C, Table 2), also increasing from 71.11% during the baseline phase to 96.74% during the stability phase ( $P < 0.05$ ) (Figure 2D). These two outcomes all eventually reached national standards. Although the proportion of rational duration of antibiotic prophylaxis showed an increasing trend during the intervention phase (0.10;  $P < 0.05$ ), the difference was not statistically significant (Figure 2E, Table 2). However, in the stability phase, this showed a decreasing trend ( $-1.19$ ;  $P < 0.001$ ), which did not meet the national standard ( $\geq 90\%$ ). Figure 2F showed the proportion of rational duration, increasing from 2.84% during the baseline phase to 42.63% during the stability phase ( $P < 0.05$ ).

### Trends in resistance rates for common gram-negative bacilli and incidence rate of MRSA, 2011–2016

Time series analysis demonstrated a significant increase in the resistance rates of *E. coli* to carbapenems during 2011–2016 ( $P<0.05$ ). The  $\beta$  value indicated that the resistance rates of *E. coli* to imipenem and meropenem increased by 0.27% and 0.22% each year, respectively. However, the resistance rates of *E. coli* to levofloxacin and ciprofloxacin significantly decreased by 1.62% and 1.40% each year, respectively ( $P<0.01$  and  $P<0.001$ ) (Table 3).

**Table 3** Trend changes in antimicrobial resistance of *E. coli* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate(%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	0	0	0.1	0.4	0.5	1.5	Increasing	0.2657	0.0239
Meropenem	0	0	0	0.3	0.3	1.3	Increasing	0.2200	0.0471
Levofloxacin	61.3	61.3	59.1	57.7	55.5	53.9	Decreasing	-1.6191	0.0013
Ciprofloxacin	64.3	64.3	61.2	61.4	58.7	58.2	Decreasing	-1.4038	0.0002

Time series analysis demonstrated a significant increase in the resistance rates of *K. pneumoniae* to carbapenems ( $P<0.05$ ). The  $\beta$  value indicated that the resistance rates of *K. pneumoniae* to imipenem and meropenem increased by 1.29% and 1.14% each year, respectively. The resistance rates of *K. pneumoniae* to fluoroquinolones (FQs) remained stable (Table 4).

**Table 4** Trend changes in antimicrobial resistance of *K. pneumoniae* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate(%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	2.0	1.5	1	4.8	7.1	6.9	Increasing	1.2937	0.049
Meropenem	1.8	1.5	1	4.1	6.2	6.4	Increasing	1.1381	0.047

Levofloxacin	27.9	27.9	18.4	12.9	14.6	15.2	Stable	-3.0218	0.0973
Ciprofloxacin	28.9	28.9	20.2	15.5	17.0	19.0	Stable	-2.4467	0.1643

Time series analysis showed a significant decrease in the resistance rates of *P. aeruginosa* to FQs ( $P<0.05$  and  $P<0.01$ ). The  $\beta$  value indicated that the resistance rate of *P. aeruginosa* to levofloxacin and ciprofloxacin decreased by 4.78% and 2.27% each year, respectively. Resistance rates of *P. aeruginosa* to carbapenems remained stable (Table 5).

**Table 5** Trend changes in antimicrobial resistance of *P. aeruginosa* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate(%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	23.1	20.9	15.2	16.5	15.3	15.8	Stable	-1.4811	0.1008
Meropenem	18.2	16.2	10.1	12.9	11.4	11.4	Stable	-1.2977	0.1140
Levofloxacin	28.1	28.1	20.5	10.0	10.1	8.1	Decreasing	-4.7833	0.0137
Ciprofloxacin	18.2	18.2	13.5	11.6	10.5	7.5	Decreasing	-2.2677	0.0011

Our study showed that the incidence rate of nosocomial MRSA decreased significantly by 5.26% each year, declining from 68.0% (2011) to 37.5% (2016) ( $P<0.001$ ) (Supplementary Table S1).

## Correlation between antibiotic consumption and AMR

Because carbapenems and FQs are often used for nosocomial infection, we focused on evaluating the impact of use of these drugs on AMR. We found that the intensity of consumption of imipenem/cilastatin significantly increased from 0.59 to 1.36 DDD/100 bed-days ( $P<0.01$ ). However, the intensity of consumption of FQs significantly decreased

each year ( $P < 0.01$  and  $P < 0.05$ ), respectively (Supplementary Table S2).

Increased consumption of imipenem/cilastatin was correlated with the prevalence of imipenem-resistant *E. coli*, ( $r = 0.8651$ ,  $P < 0.05$ ). Similarly, decreased consumption of FQs was associated with the decreased resistance rate of *E. coli* to levofloxacin and ciprofloxacin ( $r = 0.8954$  and  $r = 0.8950$ , respectively;  $P < 0.05$ ) (Table 6).

**Table 6** Correlation between antibiotic intensity of consumption and resistance rates of *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and incidence rate of MRSA

Antibiotics	<i>E. coli</i>		<i>K. pneumoniae</i>		<i>P. aeruginosa</i>		MRSA	
	r	p	r	p	r	p	r	p
Imipenem/cilastatin	0.8651	0.0261	0.9050	0.0131	-0.7477	0.0875	-0.9611	0.0022
Meropenem	0.3252	0.5295	0.4095	0.4201	0.3672	0.4739	0.0012	0.9982
Levofloxacin	0.8954	0.0158	0.7523	0.0844	0.8954	0.0159	0.9450	0.0045
Ciprofloxacin	0.8950	0.0160	0.9209	0.0091	0.9282	0.0075	0.8883	0.0180

Antibiotics refer to intensity of consumption (DDD/100 bed-days); bacteria (*E. coli*, *K. pneumoniae*, and *P. aeruginosa*) refer to their resistance rates (%) to antibiotics; MRSA refers to incidence rate of MRSA (%).

r: correlation coefficient.

There was a relationship between the increased resistance rate of *K. pneumoniae* to imipenem/cilastatin and increased intensity of consumption of imipenem/cilastatin ( $r = 0.9050$ ,  $P < 0.05$ ). Although time series analysis showed a stable trend in the resistance rate of *K. pneumoniae* to ciprofloxacin (Table 4), there was still a significantly positive correlation between the prevalence of ciprofloxacin-resistant *K. pneumoniae* and use of ciprofloxacin ( $r = 0.9209$ ,  $P < 0.01$ ) (Table 6).

Table 6 indicated that the resistance rate of *P. aeruginosa* to FQs was correlated with the consumption of FQs ( $r = 0.8954$ ,  $P < 0.05$  for levofloxacin and  $r = 0.9282$ ,  $P < 0.01$  for ciprofloxacin).

1  
2  
3 The incidence rate of MRSA was positively correlated with the consumption of  
4 FQs( $r=0.9450$ ,  $P < 0.01$  for levofloxacin and  $r=0.8883$ ,  $P < 0.05$  for ciprofloxacin). However,  
5  
6  
7 we found that the incidence rate of MRSA was negatively correlated with the consumption of  
8  
9  
10 imipenem/cilastatin ( $r= - 0.9611$ ,  $P < 0.01$ ) (Table 6).  
11  
12  
13

## 14 15 **DISCUSSION**

16  
17 The global mortality attributable to AMR is estimated to reach 10 million annually by  
18  
19  
20 2050, which would make it one of the leading causes of death, with an economic impact of  
21  
22 up to 100 trillion US dollars (USD).<sup>16</sup>Therefore, many countries worldwide have  
23  
24 implemented AMS, with many positive effects in the rational use of antibiotics and health  
25  
26 care cost savings.<sup>17-21</sup>  
27  
28

29 The implementation of AMS in our hospital is managed by clinical pharmacists and  
30 supported by the DTC, while multiple sectors participate in it. AMS includes a multifaceted  
31  
32 approach to combat the spread of AMR. Except the regular management strategy, our  
33  
34 hospital established the reward and punishment mechanism aiming to arouse the doctor's  
35  
36 attention to the rational use of antibiotics. After many years of AMS, the proportion of  
37  
38 antibiotic prescriptions decreased to 13.21% among outpatients and 34.65% among inpatients.  
39  
40 The intensity of antibiotic consumption was reduced to 37.38 DDD/100 bed-days. These  
41  
42 outcomes are similar to the study by Bao *et al.*<sup>15</sup>Regarding antibiotic prophylaxis in type I  
43  
44 incision operations, the proportion of antibiotic prophylaxis decreased to 18.93% and the  
45  
46 proportion of rational timing of the initial dose increased to 96.74%. Only the proportion of  
47  
48 rational duration of antibiotic prophylaxis (42.63%) did not reach the national standard, for  
49  
50 the following reasons. First, coronary artery bypass graft (CABG) surgery belongs to type I  
51  
52 incision operations, according to the Clinical Practice Guidelines for Antimicrobial  
53  
54 Prophylaxis in Surgery,<sup>22</sup>the duration of prophylaxis for cardiothoracic procedures is up to 48  
55  
56  
57  
58  
59  
60

1  
2  
3 hours, with no supporting evidence. Chinese Guidelines suggest prophylactic duration be no  
4  
5 more than 48 hours. But CABG involves important viscera, in which the consequences of  
6  
7 infection would be severe. Therefore, doctors hesitate to stop antibiotics within 48 hours after  
8  
9 surgery. Second, in orthopedic surgeries, such as open reduction and plate or screw internal  
10  
11 fixation of fractures, in consideration of implants doctors also hesitate to stop antibiotics  
12  
13 within 24 hours after surgery. Third, the difficult doctor-patient relationships in China make  
14  
15 physicians hesitant about premature discontinuation of antibiotics.  
16  
17

18  
19 The aim of AMS is to limit the prevalence of AMR. The results showed that with  
20  
21 decreased intensity of FQ consumption, the resistance rates of *E. coli* and *P.aeruginosa* to  
22  
23 FQs and incidence rate of MRSA showed decreasing trends, and they were positively  
24  
25 correlated. This implied that controlling the use of FQs might limit the prevalence of AMR as  
26  
27 well as limit the emergence of MRSA; the latter is consistent with previous studies.<sup>23,24</sup> Other  
28  
29 studies<sup>25-28</sup> have reported that a reduction in second/third-generation cephalosporins and  
30  
31 clindamycin contributed to a reduction in both incidence rate of MRSA and prevalence  
32  
33 density of MRSA bacteremia. In our study, we also found that the incidence rate of MRSA  
34  
35 was negatively correlated with imipenem/cilastatin use, which was difficult to explain. To our  
36  
37 knowledge, few studies have obtained results similar to ours. Lai *et al.* reported<sup>29</sup> a significant  
38  
39 correlation between increased use of linezolid and teicoplanin and decreased prevalence of  
40  
41 MRSA. Therefore, we theorize that the reduced use of non-special grade antibiotics (such as  
42  
43 FQs and others) leads to a compensatory increased use of carbapenems; however, this  
44  
45 negative correlation requires further exploration. In addition, we found the resistance rate of  
46  
47 *E. coli* and *K.pneumoniae* to carbapenems showed an increasing trend, meaning that  
48  
49 carbapenem-resistant Enterobacteriaceae (CRE) could pose a serious threat. On March 3,  
50  
51 2017, the NHFPC issued a Notice Regarding Further Reinforcement in Management of  
52  
53 Clinical Application of Antibacterial to Control Bacteria Resistance, which required medical  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 institutions to gather, archive, and analyze patient information with respect to the use of  
4 carbapenems, to help control the prevalence of CRE.<sup>30</sup>  
5  
6

7  
8 CHINET surveillance of AMR in China reported the resistance trends from 2005 to  
9  
10 2014, using data from 19 hospitals.<sup>31</sup>In our hospital, the resistance rates of *E. coli*,  
11  
12 *K.pneumoniae*, and *P.aeruginosa* to imipenem/cilastatin and meropenem in 2014 (0.4% and  
13  
14 0.9%, 4.8% and 4.1%, 16.5% and 12.9%, respectively) were significantly lower than those  
15  
16 reported by CHINET (0.9% and 1.0%, 10.5% and 13.4%, 26.6% and 24.3%, respectively).  
17  
18 This proved that AMS in our hospital played an important role in control of AMR.  
19  
20

21  
22 Some limitations of this study should be noted. First, this was a retrospective  
23  
24 observational study without simultaneous control group, the bias couldn't be well controlled,  
25  
26 it was less convincing than a prospective, controlled study design. So the favorable results  
27  
28 obtained can not be attributed solely to the pharmacist intervention, which were affected by  
29  
30 many factors. Second, because AMS has been ongoing for many years, several different  
31  
32 clinical pharmacists have successively participated in the evaluation of prophylactic antibiotic  
33  
34 use; therefore, the evaluation results might be affected slightly by individual differences.  
35  
36  
37  
38  
39

## 40 **CONCLUSION**

41  
42  
43 This study demonstrated that AMS in our hospital could reduce and optimize antibiotic  
44  
45 use, declining bacterial resistance to FQs was associated with its reduced consumption.  
46  
47 Clinical pharmacists played an important role in improving the rational use of antibiotics,  
48  
49 however, hospital infection prevention and control measures, national policy guidance all  
50  
51 contributed to it. The findings of our study indicate some directions to pursue in controlling  
52  
53 the prevalence of CRE and MRSA. AMR is rising worldwide, so continual effort regarding  
54  
55 AMS is critical not only in large hospitals but also in primary or community hospitals.  
56  
57  
58  
59  
60

**Acknowledgments** The authors thank Guosheng Feng and Zhaohui Tong, directors of Beijing Chaoyang Hospital, for supporting and promoting antimicrobial stewardship work. We also thank Analisa Avila, ELS, of Liwen Bianji, Edanz Group China ([www.liwenbianji.cn/ac](http://www.liwenbianji.cn/ac)), for editing the English text of a draft of this manuscript.

**Contributors** LHL was the leader of AMS and responsible for supervising the work, work plan, and manuscript review. HGW was responsible for carrying out AMS and collecting, analyzing, and reporting data; she wrote this manuscript and made some amendments after review. HW was responsible for statistical analysis and wrote the analysis method in the manuscript. XJY, HZ, BYL, GC, ZKY, YW, XLC, YYZ, RZ, ZHW, HY were all involved in the different aspects of data collection. PW and CXY provided the bacterial resistance data. All authors were involved in data verification.

**Funding** There is no specific funding for this study.

**Competing interests** None declared.

**Patient consent** Not required.

**Ethics approval** Beijing Chaoyang Hospital Ethics Committee.

**Data sharing statement** No additional unpublished data are available.

## REFERENCES

1. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog Glob Health* 2015;109(7):309-18.
2. Xiao YH, Giske CG, Wei ZQ, *et al.* Epidemiology and characteristics of antimicrobial resistance in China. *Drug Resist Updat* 2011;14(4-5):236-50.
3. World Health Organization. Global strategy for containment of antimicrobial resistance. 2001(WHO/CDS/CSR/DRS/2001.2).
4. National Health and Family Planning Commission of the People's Republic of China. Notice regarding National Special Measure Scheme on Clinical Use of Antibiotics[in Chinese].2011.<http://www.nhfpc.gov.cn/zwgkzt/wsbysj/201104/51376.shtml>

- 1  
2  
3 5. Zhang HX, Li X, Huo HQ, *et al.* Pharmacist interventions for prophylactic antibiotic use in urological  
4 inpatients undergoing clean or clean-contaminated operations in a Chinese hospital. *PLoS One*  
5 2014;9(2):e88971.  
6  
7
- 8  
9 6. Davey P, Brown E, Charani E, *et al.* Interventions to improve antibiotic prescribing practices for hospital  
10 inpatients. *Cochrane Database Syst Rev* 2013;(4):CD003543.  
11  
12
- 13 7. Ma X, Xie J, Yang Y, *et al.* Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant  
14 organism isolates in critically ill patients: a pre-post study from a single center. *BMC Infect Dis*  
15 2016;16(1):704.  
16  
17
- 18 8. Xu J, Duan X, Wu H, *et al.* Surveillance and correlation of antimicrobial usage and resistance of *Pseudomonas*  
19 *aeruginosa*: a hospital population-based study. *PLoS One* 2013;8(11):e78604.  
20  
21
- 22 9. Horikoshi Y, Suwa J, Higuchi H, *et al.* Sustained pediatric antimicrobial stewardship program with consultation  
23 to infectious diseases reduced carbapenem resistance and infection-related mortality. *Int J Infect Dis*  
24 2017;64:69-73.  
25  
26
- 27 10. Wushouer H, Zhang ZX, Wang JH, *et al.* Trends and relationship between antimicrobial resistance and  
28 antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data,  
29 2014-2016. *J Infect Public Health* 2018;11(3):339-346.  
30  
31
- 32 11. Cusini A, Herren D, Bütikofer L, *et al.* Intra-hospital differences in antibiotic use correlate with antimicrobial  
33 resistance rate in *Escherichia coli* and *Klebsiella pneumoniae*: a retrospective observational study. *Antimicrob*  
34 *Resist Infect Control* 2018;7:89.  
35  
36
- 37 12. Notice Regarding Implementing Stewardship of Antibacterial Use in Clinic in April 2014 [in  
38 Chinese]. 2014. <http://www.nhfpc.gov.cn/zyygj/s3593/201404/49973560ddde4293a489b158081d777c.shtml>  
39  
40  
41  
42  
43  
44  
45  
46  
47
- 48 13. National Health and Family Planning Commission of the People's Republic of China. Regulations on Clinical  
49 Applications of Antibiotics [in  
50 Chinese]. 2012. <http://www.nhfpc.gov.cn/zyygj/s3593/201205/e5efd852b86c4afa8b09a0e58e09e10e.shtml>  
51  
52  
53
- 54 14. World Health Organization. Collaborating Center for Drug Statistics Methodology: Guidelines for ATC  
55 classification and DDD assignment  
56 2017. [http://www.who.cn/filearchive/publications/2017\\_guidelines\\_webpdf](http://www.who.cn/filearchive/publications/2017_guidelines_webpdf).  
57  
58  
59
- 60 15. Bao L, Peng R, Wang Y, *et al.* Significant reduction of antibiotic consumption and patients' costs after an

- 1  
2  
3 action plan in China. 2010-2014. *PLoS One* 2015;10(3):e0118868.
- 4  
5 16. Alawi MM, Darwesh BM. A stepwise introduction of a successful antimicrobial stewardship program.  
6  
7 Experience from a tertiary care university hospital in Western, Saudi Arabia. *Saudi Med J*  
8  
9 2016;37(12):1350-1358.
- 10  
11 17. Song P, Li W, Zhou Q. An outpatient antibacterial stewardship intervention during the journey to JCI  
12  
13 accreditation. *BMC Pharmacol Toxicol* 2014;15:8.
- 14  
15 18. Dinh A, Duran C, Davido B, *et al.* Impact of an antimicrobial stewardship program to optimize antimicrobial  
16  
17 use for outpatients at emergency department. *J Hosp Infect* 2017 Jul 8. pii: S0195-6701(17)30387-0.
- 18  
19 19. Doernberg SB, Dudas V, Trivedi KK. Implementation of an antimicrobial stewardship program targeting  
20  
21 residents with urinary tract infections in three community long-term care facilities: a quasi-experimental  
22  
23 study using time-series analysis. *Antimicrob Resist Infect Control* 2015;4:54.
- 24  
25 20. Jenkins TC, Knepper BC, Shihadeh K, *et al.* Long-term outcomes of an antimicrobial stewardship program  
26  
27 implemented in a hospital with low baseline antibiotic use. *Infect Control Hosp Epidemiol*  
28  
29 2015;36(6):664-72.
- 30  
31 21. Li Z, Cheng B, Zhang K, *et al.* Pharmacist-driven antimicrobial stewardship in intensive care units in East  
32  
33 China: A multicenter prospective cohort study. *Am J Infect Control* 2017;45(9):983-9.
- 34  
35 22. Bratzler DW, Dellinger EP, Olsen KM, *et al.* Clinical practice guidelines for antimicrobial prophylaxis in  
36  
37 surgery. *Am J Health Syst Pharm* 2013;70(3):195-283.
- 38  
39 23. Charbonneau P, Parienti JJ, Thibon P, *et al.* Fluoroquinolone use and methicillin-resistant *Staphylococcus*  
40  
41 *aureus* isolation rates in hospitalized patients: a quasi experimental study. *Clin Infect Dis*  
42  
43 2006;42(6):778-84.
- 44  
45 24. Weber SG, Gold HS, Hooper DC, *et al.* Fluoroquinolones and the risk for methicillin-resistant *Staphylococcus*  
46  
47 *aureus* in hospitalized patients. *Emerg Infect Dis* 2003;9(11):1415-22.
- 48  
49 25. Aldeyab MA, Scott MG, Kearney MP, *et al.* Impact of an enhanced antibiotic stewardship on reducing  
50  
51 methicillin-resistant *Staphylococcus aureus* in primary and secondary healthcare settings. *Epidemiol Infect*  
52  
53 2014;142(3):494-500.
- 54  
55 26. Lawes T, Edwards B, Lopez-Lozano JM, *et al.* Trends in *Staphylococcus aureus* bacteraemia and impacts of  
56  
57 infection control practices including universal MRSA admission screening in a hospital in Scotland,  
58  
59 2006-2010: retrospective cohort study and time-series intervention analysis. *BMJ Open* 2012;2(3).
- 60

- 1  
2  
3 27. Tacconelli E, De Angelis G, Cataldo MA, *et al.* Does antibiotic exposure increase the risk of  
4 methicillin-resistant *Staphylococcus aureus* (MRSA) isolation? A systematic review and meta-analysis. *J*  
5 *Antimicrob Chemother* 2008;61(1):26-38.  
6  
7  
8  
9 28. Borde JP, Kaier K, Steib-Bauert M, *et al.* Feasibility and impact of an intensified antibiotic stewardship  
10 programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center.  
11 *BMC Infect Dis* 2014;14:201.  
12  
13  
14  
15 29. Lai CC, Chu CC, Cheng A, *et al.* Correlation between antimicrobial consumption and incidence of  
16 health-care-associated infections due to methicillin-resistant *Staphylococcus aureus* and  
17 vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010. *J Microbiol*  
18 *Immunol Infect* 2015;48(4):431-6.  
19  
20  
21  
22  
23 30. National Health and Family Planning Commission ( NHFPC ) of the People's Republic of China. Notice  
24 regarding Further reinforcement the Management of Clinical Application of Antibacterial to Control  
25 Bacteria Resistant [in Chinese].2017.  
26  
27 <http://www.nhfpc.gov.cn/yzygj/s7659/201703/d2f580480cef4ab1b976542b550f36cf.shtml>.  
28  
29  
30  
31 31. Hu FP, Guo Y, Zhu DM, *et al.* Resistance trends among clinical isolates in China reported from CHINET  
32 surveillance of bacterial resistance, 2005-2014. *Clin Microbiol Infect* 2016;22 Suppl 1:S9-14.  
33  
34  
35  
36  
37  
38  
39

#### 40 **Figure legends:**

#### 41 **Figure 1. Changes in proportion of antibiotic prescriptions and intensity of** 42 **consumption.**

43  
44  
45  
46  
47 Time series curves of each monthly value of antibiotic prescribing proportions, plotted for  
48 outpatients (A) and inpatients (C). Each monthly value of intensity of antibiotic consumption  
49 was plotted for inpatients (E). The Bonferroni test was conducted to compare these data in  
50 three stages, for antibiotic prescribing proportion among outpatients (B) and inpatients (D),  
51 and intensity of antibiotic consumption (F). Stage 1, Stage 2, and Stage 3 on the x-axis  
52 represent the baseline phase, intervention phase, and stability phase, respectively.  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure 2. Changes in antibiotic prophylaxis in type I incision operations.**  
4

5 Time series curves of each monthly value of antibiotic prophylaxis were plotted for  
6 proportion of prophylaxis (A), proportion of rational timing (C), and proportion of rational  
7 duration (E). These data in three stages were compared by Bonferroni test (B, D, and F).  
8 Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase,  
9 and stability phase, respectively.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only




Figure 1. Changes in proportion of antibiotic prescriptions and intensity of consumption.

Time series curves of each monthly value of antibiotic prescribing proportions, plotted for outpatients (A) and inpatients (C). Each monthly value of intensity of antibiotic consumption was plotted for inpatients (E).

The Bonferroni test was conducted to compare these data in three stages, for antibiotic prescribing proportion among outpatients (B) and inpatients (D), and intensity of antibiotic consumption (F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.

388x207mm (144 x 144 DPI)




Figure 2. Changes in antibiotic prophylaxis in type I incision operations. Time series curves of each monthly value of antibiotic prophylaxis were plotted for proportion of prophylaxis (A), proportion of rational timing (C), and proportion of rational duration (E). These data in three stages were compared by Bonferroni test (B, D, and F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.

546x292mm (144 x 144 DPI)



## Supplementary materials

**Table S1** Trend changes in incidence rate of methicillin-resistant *Staphylococcus aureus* from 2011 to 2016

	By year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	<i>P</i>
<b>Incidence rate (%)</b>	68.0	60.3	58.3	49.8	51.5	37.5	Decreasing	-5.2565	0.0007

**Table S2** Usage trend changes of carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Antibiotic consumption (DDD/100 bed-days) by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	<i>P</i>
Imipenem/cilastatin	0.59	0.71	0.79	1.17	1.16	1.36	Increasing	0.1599	0.0013
Meropenem	0.86	0.34	0.29	0.38	0.66	0.69	Stable	-0.0116	0.9193
Levofloxacin	11.18	9.70	10.64	7.74	7.71	6.35	Decreasing	-0.9292	0.0033
Ciprofloxacin	6.17	4.12	2.49	0.91	0.66	0.45	Decreasing	-1.1811	0.0461

DDD, defined daily dose.

## STROBE Statement—checklist of items that should be included in reports of observational studies

**Our research met all the items of STROBE statement.**

	Item No	Recommendation	Page number
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-5
Objectives	3	State specific objectives, including any prespecified hypotheses	3-5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2,4,5,8,9
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Not Applicable for this study.
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	1,2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	8-10
		(c) Explain how missing data were addressed	None
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	Not Applicable for this study
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy			
	(e) Describe any sensitivity analyses	8-10	

Continued on next page

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Results</b>		<b>Page number</b>	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	2-3
		(b) Give reasons for non-participation at each stage	Applicable for this study
		(c) Consider use of a flow diagram	Applicable for this study
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Applicable for this study
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Applicable for this study
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Applicable for this study
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	19-21
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	4,22
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-22
Generalisability	21	Discuss the generalisability (external validity) of the study results	20-22
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	None

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use and drug resistance in a Chinese hospital, 2010–2016: a retrospective observational study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-026072.R2
Article Type:	Research
Date Submitted by the Author:	29-May-2019
Complete List of Authors:	Wang, Huaguang; Beijing Chaoyang Hospital, Wang, Han; School of Public Health, Peking University, Department of Maternal and Child Health Yu, Xiaojia; Beijing Chaoyang Hospital Zhou, Hong; Beijing Chaoyang Hospital Li, Boyu; Beijing Chaoyang Hospital Chen, Gang; Beijing Chaoyang Hospital Ye, Zhikang; Beijing Chaoyang Hospital Wang, Ying Cui, Xiangli; Beijing Chaoyang Hospital Zheng, Yunying; Beijing Chaoyang Hospital Zhao, Rui; Beijing Chaoyang Hospital Yang, Hui; Beijing Chaoyang Hospital Wang, Zihui; Beijing Chaoyang Hospital Wang, Peng; Beijing Chaoyang Hospital Yang, Chunxia; Beijing Chaoyang Hospital Liu, Lihong; Beijing Chaoyang Hospital,
<b>Primary Subject Heading</b>:	Medical management
Secondary Subject Heading:	Infectious diseases, Pharmacology and therapeutics, Public health
Keywords:	antimicrobial stewardship, clinical pharmacist, antibiotic use, prophylactic antibiotic use, type-I incision operation, antimicrobial resistance

SCHOLARONE™  
Manuscripts

1  
2  
3 **Impact of antimicrobial stewardship managed by clinical pharmacists on antibiotic use**  
4 **and drug resistance in a Chinese hospital, 2010–2016: a retrospective observational**  
5 **study**  
6  
7  
8  
9

10 Huaguang Wang<sup>1</sup>, Han Wang<sup>2</sup>, Xiaojia Yu<sup>1</sup>, Hong Zhou<sup>1</sup>, Boyu Li<sup>1</sup>, Gang Chen<sup>1</sup>, Zhikang  
11 Ye<sup>1</sup>, Ying Wang<sup>1</sup>, Xiangli Cui<sup>1</sup>, Yunying Zheng<sup>1</sup>, Rui Zhao<sup>1</sup>, Hui Yang<sup>1</sup>, Zihui Wang<sup>1</sup>, Peng  
12 Wang<sup>3</sup>, Chunxia Yang<sup>3</sup>, Lihong Liu<sup>1\*</sup>  
13  
14

15  
16  
17 <sup>1</sup> Huaguang Wang, <sup>1</sup> Xiaojia Yu, <sup>1</sup> Hong Zhou, <sup>1</sup> Boyu Li, <sup>1</sup> Gang Chen, <sup>1</sup> Zhikang Ye, <sup>1</sup>  
18 Xiangli Cui, <sup>1</sup> Ying Wang, <sup>1</sup> Yunying Zheng, <sup>1</sup> Rui Zhao, <sup>1</sup> Hui Yang, <sup>1</sup> Zihui Wang, <sup>1</sup> Lihong  
19 Liu : Department of Pharmacy, Beijing Chaoyang Hospital Affiliate of Capital University of  
20 Medical Sciences, Beijing, China  
21  
22  
23

24  
25  
26 <sup>2</sup> Han Wang: Department of Maternal and Child Health, School of Public Health, Peking  
27 University, Beijing, China  
28  
29

30  
31 <sup>3</sup> Peng Wang, <sup>3</sup> Chunxia Yang: Department of Infectious Diseases and Clinical Microbiology,  
32 Beijing Chaoyang Hospital Affiliate of Capital University of Medical Sciences, Beijing,  
33 China  
34  
35  
36

37 \*Corresponding author: [liulihong@bjcyh.com](mailto:liulihong@bjcyh.com) Tel: +86-10-85231788

38  
39  
40 Postal address: 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing, China, 100020

41  
42 Word count: 4121  
43  
44  
45  
46

## 47 **ABSTRACT**

48  
49 **Objectives:** “National Special Stewardship in the Clinical Use of Antibiotics” was put  
50 forward in July, 2011 in China. We aimed to retrospectively evaluate the impact of  
51 antimicrobial stewardship (AMS) managed by clinical pharmacists on antibiotic utilization,  
52 prophylaxis and antimicrobial resistance (AMR).  
53  
54  
55  
56  
57

58  
59 **Design:** This was a retrospective observational study of trends in antibiotic use and AMR in  
60

1  
2  
3 the context of AMS.  
4

5 **Setting:** Beijing Chaoyang Hospital, a 1400-bed tertiary hospital, in China.  
6

7 **Data and participants:** Antibiotic prescriptions from 820 doctors included all outpatients  
8 (N=17766637) and inpatients (N=376627) during 2010–2016. Bacterial resistance data were  
9  
10 from all inpatients (N=350699) during 2011–2016.  
11  
12

13 **Interventions:** Multi-aspect intervention measures were implemented by clinical pharmacists  
14 (13persons), e.g. formulating the activity program and performance management, advising on  
15  
16 antibacterial prescriptions and training.  
17  
18

19 **Outcome measures:** The proportion of antibiotic prescriptions among outpatients and  
20  
21 inpatients, intensity of consumption in defined daily dose (DDD)/100 bed-days, antibiotic  
22  
23 prophylaxis in type I incision operations, and resistance rates of *Escherichia coli*, *Klebsiella*  
24  
25 *pneumoniae*, and *Pseudomonas aeruginosa* were retrospectively analyzed.  
26  
27  
28

29 **Results:** The proportion of antibiotic prescriptions decreased in outpatients (from 19.38% to  
30  
31 13.21%) and in inpatients (from 64.34% to 34.65%), the intensity of consumption dropped  
32  
33 from 102.46 to 37.38 DDD/100 bed-days. The proportion of antibiotic prophylaxis decreased  
34  
35 from 98.94% to 18.93%. The proportion of rational timing of initial dose increased from  
36  
37 71.11% to 96.74%, the proportion of rational duration rose from 2.84% to 42.63%. Time  
38  
39 series analysis demonstrated the resistance rates of *E. coli* and *P. aeruginosa* to  
40  
41 fluoroquinolones decreased, the incidence rate of methicillin-resistant *Staphylococcus aureus*  
42  
43 (MRSA) also decreased; whereas the resistance rates of *E. coli* and *K. pneumoniae* to  
44  
45 carbapenems increased. The antibiotic use was partly positively correlated with AMR.  
46  
47  
48  
49

50 **Conclusions:** AMS had an important role in reducing antibiotic use and surgical antibiotic  
51  
52 prophylaxis. The AMR was positively correlated with antibiotic consumption to some extent.  
53  
54  
55

56  
57  
58 **Strengths and limitations of this study**  
59  
60

- 1
- 2
- 3 ■ Our study described the entire process of AMS, from management of antibiotic use to
- 4 AMR monitoring.
- 5
- 6
- 7
- 8 ■ Time series analysis, a better tool, was applied to analyze the change trends in antibiotic
- 9 utilization and AMR.
- 10
- 11
- 12 ■ By exploring the correlation between antibiotic use and AMR, this study may indicate
- 13 some potential directions for controlling the prevalence of CRE and MRSA.
- 14
- 15
- 16
- 17 ■ This was a retrospective observational study without simultaneous control group, the bias
- 18 couldn't be well controlled; the evaluation of prophylactic antibiotic use by different
- 19 clinical pharmacists might have individual differences.
- 20
- 21
- 22
- 23
- 24
- 25
- 26

## 27 INTRODUCTION

28

29 In 2004, the first Guidelines for the Clinical Use of Antibiotics (Guidelines for short)

30 was issued by the National Health and Family Planning Commission (NHFPC, originally

31 called the Ministry of Health) of the People's Republic of China, describing the

32 characteristics of all types of antibiotics and appropriate use in treatment and prevention of

33 infectious diseases; the Guidelines were updated in 2015. Regretfully, not all medical staff

34 knew about the Guidelines or their significance. Today, antimicrobial resistance (AMR) is

35 one of the greatest threats to global health. There are four main factors contributing to the

36 spread of AMR: inappropriate use of antibiotics in the community and in hospitals, misuse of

37 antibiotics in animal production and agriculture, and the presence of resistant bacteria in the

38 environment. The former three factors could aggravate the last one.<sup>1</sup> Chinese data from the

39 Ministry of Health National Antibacterial Resistance Surveillance Net (MOHNARIN)

40 showed that AMR has been rising steadily each year.<sup>2</sup>

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 In 2001 the World Health Organization (WHO) began to take measures to combat the

58 spread of AMR and strongly recommended governments to implement antimicrobial

59

60



1  
2  
3 stewardship (AMS).<sup>3</sup>On World Health Day 2011, AMR was also selected as the theme. In  
4  
5 response to AMR, in 2011 the NHFPC of China put forward “National Special Stewardship  
6  
7 in the Clinical Use of Antibiotics”,<sup>4</sup> the historically strictest management of antibiotics up to  
8  
9 that date. The NHFPC set many goals for the clinical use of antibiotics, including restriction  
10  
11 of antibiotic use in outpatients and inpatients and restriction of antibiotic prophylactic use in  
12  
13 clean operations, to promote rational antibiotic use and control AMR. These goals are  
14  
15 described in detail below. This special stewardship policy mainly covered secondary and  
16  
17 tertiary public hospitals and took effect on July 1, 2011. After that date, these hospitals were  
18  
19 required to report data of antibiotic use to the government every month.  
20  
21  
22

23  
24 In recent years, some studies have reported that AMS had positive effects on controlling  
25  
26 antibiotic-resistant pathogens, rational use of antibiotics, and cost savings,<sup>5,6</sup> highlighting the  
27  
28 importance of AMS. There were also some studies<sup>7-11</sup> that analyzed the correlation between  
29  
30 antibiotic use and AMR, although these all demonstrated the effectiveness of AMS, but the  
31  
32 studied population, antibiotic and pathogen are different, and the results of correlation  
33  
34 between antibiotic use and AMR were not exactly the same.  
35  
36

37  
38 The aim of this study was to evaluate the impact of AMS on antibiotic use and AMR  
39  
40 trends, to share our successful management experience, and to identify existing problems. In  
41  
42 addition, because the doctors' prescription behaviors and antibiotic variety are different in  
43  
44 each country or region, so is the status of AMR, therefore we sought to demonstrate the  
45  
46 correlation between antibiotic use and antimicrobial resistance rate of common nosocomial  
47  
48 pathogens, using data from all inpatients in our hospital.  
49  
50

## 51 **METHODS**

### 52 **Study design**

53  
54  
55 According to the requirements of the national policy, “Special Stewardship in the  
56  
57 Clinical Use of Antibiotics” was a 3-year plan (2011–2013). In April of 2014, the NHFPC  
58  
59

1  
2  
3 issued a Notice Regarding Implementing Stewardship of Antibacterial Use in the Clinic;<sup>12</sup>its  
4  
5 aim was to continuously maintain the positive effects gained during the previous 3 years.  
6  
7 Accordingly, in our retrospective study, phases were divided into three stages, as follows.  
8  
9 Stage 1: baseline phase (July 2010 to June 2011); stage 2: intervention phase (July 2011 to  
10  
11 December 2013); and stage 3: stability phase (January 2014 to December 2016).  
12  
13  
14

## 15 **Patient and public involvement**

16  
17 The antibiotic utilization data was extracted directly from the Hospital Information  
18  
19 System (HIS) and electronic medical records of all patients (2010-2016). The patient's  
20  
21 personal information was hidden. The bacterial resistance data from all inpatients (2011-2016)  
22  
23 was provided by the Department of Infectious Diseases and Clinical Microbiology. Clinical  
24  
25 sample sources included blood, cerebrospinal fluid, pleural effusion, ascites, urine and  
26  
27 sputum, etc. Duplicate isolates, defined as the isolates of the same species that showed the  
28  
29 same susceptibility results at the same site for each patient in different days, were excluded,  
30  
31 only the first isolated strain was included in the study (excluding isolates of surveillance  
32  
33 cultures).  
34  
35  
36  
37

## 38 **Ethics statement**

39  
40 This study was approved by the Ethics Committee of Beijing Chaoyang Hospital  
41  
42 (Approval Number: 2017-11-28-3). Because the patient's privacy was not violated in the  
43  
44 study, so the Ethics Committee agreed exemption applications of informed consent.  
45  
46  
47

## 48 **Multi-aspect intervention measures**

### 49 **Organization construction**

50  
51 To implement the program “National Special Stewardship in the Clinical Use of  
52  
53 Antibiotics”, an AMS group was set up in our hospital, which was attached to the Drug and  
54  
55 Therapeutics Committee (DTC). The AMS group was composed of administrators, clinicians,  
56  
57 infectious disease physicians, pharmacists, microbiologists, and information staff, and  
58  
59  
60

1  
2  
3 included a leadership group and expert group. The leadership group was responsible for work  
4 deployment and supervision whereas the expert group was responsible for technical guidance,  
5  
6 participation in consultations, training doctors on rational use of antibiotics and  
7  
8 implementation of AMS monitoring (such as data collection and report, prescription review  
9  
10 and feedback, AMR monitoring, etc). Generally the medical department led AMS in many  
11  
12 hospitals in China, but in our hospital, the pharmacy department was the leading department,  
13  
14 for the following reasons. (1) The pharmacy department in our hospital is not only a technical  
15  
16 section but also a functional section. The pharmacy director is responsible for medication use.  
17  
18 (2) There are many clinical pharmacists, such as infectious disease pharmacists who have  
19  
20 sufficient knowledge and clinical experience to manage AMS. (3) Clinical pharmacists work  
21  
22 in the clinical departments every day, so they could give their professional advice regarding  
23  
24 antibiotic use directly to doctors.  
25  
26  
27  
28  
29

### 30 **Formulating the activity program and administrative intervention**

31  
32  
33 The AMS group formulated the activity program of stewardship and some regulations  
34 on antibiotic use were issued, as follows. (1) Antibiotic classification management system.  
35  
36 All antibiotics were classified as non-restricted, restricted, and special grade antibiotics.  
37  
38 Physicians with different professional titles were matched to the corresponding grade of  
39  
40 antibiotic prescribing privileges. (2) Management system of antibiotic prescribing privileges.  
41  
42 In May of 2012, the Regulations on Clinical Applications of Antibiotics were issued by the  
43  
44 NHFPC, which took effect on August, 1, 2012. These were the first valid regulations on  
45  
46 antibiotics in China.<sup>13</sup>The regulations required that physicians would not be given antibiotic  
47  
48 prescribing privileges until they passed an exam, after completing training on rational use of  
49  
50 antibiotics. This prescribing privilege restriction was embedded into the Hospital Information  
51  
52 System (HIS). (3) Regulation of perioperative prophylactic antibiotic use in clean operations,  
53  
54 in which the choice of antibiotics, dose, timing of the initial dose, and duration of antibiotic  
55  
56  
57  
58  
59  
60

prophylaxis were described.

According to the requirements of the national antibiotic stewardship program,<sup>4</sup> the AMS group established the goals for antibiotic application in the hospital (Table 1).

**Table 1** Goals of clinical antibiotic use established by the NHFPC in 2011

Antibiotic outcome measures	Goals
1. Proportion of inpatients receiving antibiotics	≤ 60%
2. Proportion of outpatients receiving antibiotics	≤ 20%
3. Intensity of inpatients' antibiotic consumption	≤ 40 DDD/100 bed-days
4. Proportion of antibiotic prophylaxis in patients receiving type I incision operations/clean operations	≤ 30%
5. Timing of initial dose of preoperative antibiotic prophylaxis	Within 0.5–2 h before surgical incision
6. Duration of antibiotic prophylaxis in patients receiving type I incision operations/clean operations	Within 24 h after the end of operation

### Performance management

Every year, the directors of clinical departments were asked by the director of the hospital to sign responsibility agreements for antibiotic use. Hospital leaders and the pharmacy director, together with clinical pharmacists, established or updated the performance appraisal system for antibiotic use, which indicated the circumstances to be rewarded or penalized. For example, if clinical departments did not accomplish their goals, the directors would be fined 1000–3000CNY, and doctors would be fined 300–500CNY. If the clinical departments accomplished their goals, the directors would be rewarded with 1000–5000 CNY and doctors with 300–1000 CNY, which were greater than the amounts of fines.

### Antibiotic prescription evaluation and training

Retrospective rationality evaluation of antibiotic prescriptions for outpatients,

1  
2  
3 emergency room patients, and inpatients was performed monthly by clinical pharmacists. For  
4  
5 example, some doctors used moxifloxacin to treat urinary tract infections, which didn't  
6  
7 conform to the recommendation of guideline and medicine specification; the combination of  
8  
9 imipenem/cilastatin and metronidazole was unsuitable, the latter was unnecessary. Clinical  
10  
11 pharmacists would contact the doctors to modify the prescriptions. Inappropriate  
12  
13 prescriptions would be flagged in the Antibacterial Monitoring Report published by the  
14  
15 pharmacy department each month; this report was made available to all medical staff.  
16  
17 According to the frequency and severity of inappropriate prescriptions, some doctors would  
18  
19 be fined.  
20  
21  
22

23  
24 Clinical pharmacists were responsible for training the medical staff on rational use of  
25  
26 antibiotics. Training was conducted every 6 months in two forms. (1) Clinical pharmacists  
27  
28 gave lessons to the medical staff in the lecture hall, they need to complete an exam after class.  
29  
30 (2) Clinical pharmacists and the medical department jointly made online learning and exam,  
31  
32 medical staff was required to finish it. If necessary, pharmacists would go to the clinical  
33  
34 departments to give lectures.  
35  
36

### 37 **Multiple cooperation**

38  
39 Antibiotics data monitoring could not be implemented without the support of the  
40  
41 information department. At the start of AMS at our hospital, data extraction modules were  
42  
43 embedded into the HIS after discussions between clinical pharmacists and information  
44  
45 personnel. Later, an automatic prescription screening system was also included in the HIS,  
46  
47 which could intercept inappropriate prescriptions, such as repeated use or unreasonable  
48  
49 combinations. Furthermore, clinical pharmacists took part in the Core Expert Meeting of  
50  
51 Antibacterial Application held by the Infection Management Office, to discuss usage  
52  
53 problems with carbapenems and glycopeptides. If inappropriate use was confirmed by the  
54  
55 experts, the relevant physician would be penalized 100–200CNY fine.  
56  
57  
58  
59  
60

## Data collection and outcome measures

Antibiotic outcome measures are shown in Table 1 (see “Antibiotic outcome measures”). The antibiotic utilization data was collected directly from the HIS. Antibiotic consumption was standardized according to the Anatomical Therapeutic Chemical (ATC) classification system and the DDD was used as a measuring unit, as recommended by the WHO Collaborating Center for Drug Statistics Methodology.<sup>14</sup> The intensity of inpatients’ antibiotic consumption was expressed as DDD per 100 bed-days. Information of type I incision operations was extracted from inpatients’ electronic medical records. The outcome measures of AMR included the resistance rates of *Escherichia coli*, *Klebsiella pneumonia*, and *Pseudomonas aeruginosa* and incidence rate of methicillin-resistant *Staphylococcus aureus* (MRSA) in our hospital. The bacteriological data were obtained from the clinical microbiology laboratory. We analyzed the correlation between antibiotic consumption and AMR.

## Statistical analysis

Segmented regression analysis of interrupted time series was used to analyze the monthly data of antibiotic utilization, which were divided into three stages (the baseline phase, intervention phase, and stability phase), to illustrate the effect of AMS. The statistical model in this study was as follows.<sup>15</sup>

$$Y_t = \beta_0 + \beta_1 \times \text{time}_t + \beta_2 \times \text{intervention}_t + \beta_3 \times \text{time after intervention}_t + \beta_4 \times \text{stability}_t + \beta_5 \times \text{time after stability}_t + e_t$$

In this model,  $Y_t$  was the average monthly value of the outcome measure at month  $t$ ;  $\beta_0$  estimates the level change in the outcome during the baseline phase;  $\beta_1$  estimates the trend change during the baseline phase;  $\beta_2$  estimates the level change during the intervention phase;  $\beta_3$  estimates the trend change during the intervention phase;  $\beta_4$  estimates the level

1  
2  
3 change during the stability phase; and  $\beta_5$  estimates the trend change during the stability phase.  
4  
5 The parameter level was the value of a time series at the beginning of a given time series; the  
6  
7 parameter trend was the rate of change in an outcome measure; *time* was a continuous  
8  
9 variable indicating time in months at time *t* starting from the baseline phase (time 0);  
10  
11 *intervention* was an indicator for time *t* occurring before (*intervention*=0) or after  
12  
13 (*intervention*=1) the multi-aspect intervention, which started at month 13 (July 2011); *time*  
14  
15 *after intervention* was a continuous variable counting the months after the intervention;  
16  
17 *stability* was an indicator for time *t* occurring before (*stability*=0) or after stability  
18  
19 (*stability*=1), which started at month 43 (January 2014); *time after stability* was a continuous  
20  
21 variable counting the months after stability. The error term,  $e_t$ , represented variation  
22  
23 unexplained by the segmented regression model.  
24  
25  
26  
27  
28

29 Comparisons of the average monthly values of outcome measures for antibiotic use  
30  
31 during the three phases were conducted using the Bonferroni test. Box charts were plotted for  
32  
33 data visualization, with error bars representing standard deviations.  
34  
35

36 In addition, a time series analysis model (autoregressive integrated moving average,  
37  
38 ARIMA)<sup>8</sup> was used to analyze the trends in annual antibiotic use, AMR trends, and incidence  
39  
40 trend of MRSA from 2011 to 2016. The  $\beta$  value indicated the variation of dependent  
41  
42 variables when independent variables changed one unit at uniform time intervals. Pearson  
43  
44 correlation coefficients were used to examine the relationships between antimicrobial  
45  
46 resistance rate, the incidence rate of MRSA, and antibiotic use.  
47  
48

49 All statistics were performed using SAS, version 9.3 (SAS Institute, Cary, NC, USA).  
50  
51 All reported *P* values were two-sided, with  $P < 0.05$  considered statistically significant.  
52  
53  
54  
55

## 56 RESULTS

### 57 Change trends in antibiotic utilization rate and intensity

Changes in the proportion of antibiotic prescriptions in outpatients and inpatients during the baseline, intervention, and stability phases are shown in Figure 1A, 1B, 1C and 1D. The associated parameters of time series analysis are summarized in Table 2. The proportion of antibiotic prescriptions in outpatients and inpatients declined by 0.33% ( $P < 0.05$ ) and by 0.59% ( $P < 0.05$ ) each month during the intervention stage, respectively. Bonferroni tests (Figure 1B) showed that the proportion of antibiotic prescriptions in outpatients was reduced from 19.38% during the baseline phase to 13.21% during the stability phase ( $P < 0.05$ ). The proportion of antibiotic prescriptions among inpatients decreased significantly from 64.34% during the baseline phase to 34.65% during the stability phase ( $P < 0.05$ ) (Figure 1D). Figure 1E and Table 2 showed that the intensity of inpatients' antibiotic consumption decreased significantly by 6.46 DDD/100 bed-days ( $P < 0.001$ ) per month during the first year of the intervention stage. Figure 1F showed the intensity of consumption dropped from the baseline phase to the stability phase (102.46 vs. 37.38 DDD/100 bed-days;  $P < 0.05$ ). All the outcomes mentioned above met the national standards. In the stability phase, the  $\beta 5$  value for the intensity of consumption (0.70;  $P < 0.001$ ) implied a gradually increasing trend; this still met national standards.

**Table 2** Time series analysis of change trends in antibiotic utilization

Antibiotic outcome measures	$\beta 1$ -trend (baseline)	$\beta 2$ -level (intervention)	$\beta 3$ -trend (intervention)	$\beta 4$ -level (stability)	$\beta 5$ -trend (stability)
Proportion-O	-0.01 (0.04)	0.55 (0.83)	-0.33 (0.12)*	0.48 (0.85)	-0.19 (0.14)
Proportion-I	-0.25 (0.10)*	-5.03 (2.22)*	-0.59 (0.29)*	3.61 (2.23)	-0.66 (0.74)
Intensity-I	-0.04 (0.04)	-7.44 (3.62)*	-6.46 (0.56)***	4.20 (1.45)**	0.70 (0.19)***
Proportion-type I	-0.10 (0.04)*	-7.26 (2.92)*	-5.71 (0.61)***	-0.18 (1.44)	-0.12 (0.12)
Timing-type I	-0.01 (0.07)	0.64 (1.72)	1.18 (0.59)*	1.63 (2.00)	-0.17 (0.24)



Duration-type I	0.28 (0.06)***	8.78 (2.15)**	0.10 (0.27)	5.35 (1.44)***	-1.19 (0.19)***
-----------------	----------------	---------------	-------------	----------------	-----------------

Outcomes of antibiotic utilization included proportion of antibiotic prescriptions in outpatients (Proportion-O), inpatients (Proportion-I), and intensity of consumption in inpatients (Intensity-I). Outcomes of antibiotic prophylaxis included proportion of prophylaxis (Proportion-type I), proportion of rational timing (Timing-type I), and proportion of rational duration (Duration-type I). Parameters of  $\beta_1$ – $\beta_5$  were expressed as mean (SE), which represented the changes in level and trend.

\* $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ .

## Change trends of antibiotic prophylaxis in type I incision operations

The proportion of antibiotic prophylaxis in patients undergoing type I incision operations was significantly reduced by 5.71% ( $P < 0.001$ ) monthly during the first year of the intervention phase (Figure 2A, Table 2), decreasing from 98.94% during the baseline phase to 18.93% during the stability phase ( $P < 0.05$ ) (Figure 2B). The proportion of rational timing of the initial dose increased by 1.18% ( $P < 0.05$ ) each month during the intervention stage (Figure 2C, Table 2), also increasing from 71.11% during the baseline phase to 96.74% during the stability phase ( $P < 0.05$ ) (Figure 2D). These two outcomes all eventually reached national standards. Although the proportion of rational duration of antibiotic prophylaxis showed an increasing trend during the intervention phase (0.10;  $P < 0.05$ ), the difference was not statistically significant (Figure 2E, Table 2). However, in the stability phase, this showed a decreasing trend ( $-1.19$ ;  $P < 0.001$ ), which did not meet the national standard ( $\geq 90\%$ ). Figure 2F showed the proportion of rational duration, increasing from 2.84% during the baseline phase to 42.63% during the stability phase ( $P < 0.05$ ).

## Trends in resistance rates for common gram-negative bacilli and incidence rate of MRSA, 2011–2016

Time series analysis demonstrated a significant increase in the resistance rates of *E. coli* to carbapenems during 2011–2016 ( $P<0.05$ ). The  $\beta$  value indicated that the resistance rates of *E. coli* to imipenem and meropenem increased by 0.27% and 0.22% each year, respectively. However, the resistance rates of *E. coli* to levofloxacin and ciprofloxacin significantly decreased by 1.62% and 1.40% each year, respectively ( $P<0.01$  and  $P<0.001$ ) (Table 3).

**Table 3** Trend changes in antimicrobial resistance of *E. coli* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate(%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	0	0	0.1	0.4	0.5	1.5	Increasing	0.2657	0.0239
Meropenem	0	0	0	0.3	0.3	1.3	Increasing	0.2200	0.0471
Levofloxacin	61.3	61.3	59.1	57.7	55.5	53.9	Decreasing	-1.6191	0.0013
Ciprofloxacin	64.3	64.3	61.2	61.4	58.7	58.2	Decreasing	-1.4038	0.0002

Time series analysis demonstrated a significant increase in the resistance rates of *K. pneumoniae* to carbapenems ( $P<0.05$ ). The  $\beta$  value indicated that the resistance rates of *K. pneumoniae* to imipenem and meropenem increased by 1.29% and 1.14% each year, respectively. The resistance rates of *K. pneumoniae* to fluoroquinolones (FQs) remained stable (Table 4).

**Table 4** Trend changes in antimicrobial resistance of *K. pneumoniae* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate(%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	2.0	1.5	1	4.8	7.1	6.9	Increasing	1.2937	0.049
Meropenem	1.8	1.5	1	4.1	6.2	6.4	Increasing	1.1381	0.047

Levofloxacin	27.9	27.9	18.4	12.9	14.6	15.2	Stable	-3.0218	0.0973
Ciprofloxacin	28.9	28.9	20.2	15.5	17.0	19.0	Stable	-2.4467	0.1643

Time series analysis showed a significant decrease in the resistance rates of *P. aeruginosa* to FQs ( $P<0.05$  and  $P<0.01$ ). The  $\beta$  value indicated that the resistance rate of *P. aeruginosa* to levofloxacin and ciprofloxacin decreased by 4.78% and 2.27% each year, respectively. Resistance rates of *P. aeruginosa* to carbapenems remained stable (Table 5).

**Table 5** Trend changes in antimicrobial resistance of *P. aeruginosa* to carbapenems and fluoroquinolones from 2011 to 2016

Antibiotic	Resistance rate(%), by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	$P$
Imipenem	23.1	20.9	15.2	16.5	15.3	15.8	Stable	-1.4811	0.1008
Meropenem	18.2	16.2	10.1	12.9	11.4	11.4	Stable	-1.2977	0.1140
Levofloxacin	28.1	28.1	20.5	10.0	10.1	8.1	Decreasing	-4.7833	0.0137
Ciprofloxacin	18.2	18.2	13.5	11.6	10.5	7.5	Decreasing	-2.2677	0.0011

Our study showed that the incidence rate of nosocomial MRSA decreased significantly by 5.26% each year, declining from 68.0% (2011) to 37.5% (2016) ( $P<0.001$ ) (Supplementary Table S1).

## Correlation between antibiotic consumption and AMR

Because carbapenems and FQs are often used for nosocomial infection, we focused on evaluating the impact of use of these drugs on AMR. We found that the intensity of consumption of imipenem/cilastatin significantly increased from 0.59 to 1.36 DDD/100 bed-days ( $P<0.01$ ). However, the intensity of consumption of FQs significantly decreased

each year ( $P < 0.01$  and  $P < 0.05$ ), respectively (Supplementary Table S2).

Increased consumption of imipenem/cilastatin was correlated with the prevalence of imipenem-resistant *E. coli*, ( $r = 0.8651$ ,  $P < 0.05$ ). Similarly, decreased consumption of FQs was associated with the decreased resistance rate of *E. coli* to levofloxacin and ciprofloxacin ( $r = 0.8954$  and  $r = 0.8950$ , respectively;  $P < 0.05$ ) (Table 6).

**Table 6** Correlation between antibiotic intensity of consumption and resistance rates of *E. coli*, *K. pneumoniae*, *P. aeruginosa*, and incidence rate of MRSA

Antibiotics	<i>E. coli</i>		<i>K. pneumoniae</i>		<i>P. aeruginosa</i>		MRSA	
	r	p	r	p	r	p	r	p
Imipenem/cilastatin	0.8651	0.0261	0.9050	0.0131	-0.7477	0.0875	-0.9611	0.0022
Meropenem	0.3252	0.5295	0.4095	0.4201	0.3672	0.4739	0.0012	0.9982
Levofloxacin	0.8954	0.0158	0.7523	0.0844	0.8954	0.0159	0.9450	0.0045
Ciprofloxacin	0.8950	0.0160	0.9209	0.0091	0.9282	0.0075	0.8883	0.0180

Antibiotics refer to intensity of consumption (DDD/100 bed-days); bacteria (*E. coli*, *K. pneumoniae*, and *P. aeruginosa*) refer to their resistance rates (%) to antibiotics; MRSA refers to incidence rate of MRSA (%).  
r: correlation coefficient.

There was a relationship between the increased resistance rate of *K. pneumoniae* to imipenem/cilastatin and increased intensity of consumption of imipenem/cilastatin ( $r = 0.9050$ ,  $P < 0.05$ ). Although time series analysis showed a stable trend in the resistance rate of *K. pneumoniae* to ciprofloxacin (Table 4), there was still a significantly positive correlation between the prevalence of ciprofloxacin-resistant *K. pneumoniae* and use of ciprofloxacin ( $r = 0.9209$ ,  $P < 0.01$ ) (Table 6).

Table 6 indicated that the resistance rate of *P. aeruginosa* to FQs was correlated with the consumption of FQs ( $r = 0.8954$ ,  $P < 0.05$  for levofloxacin and  $r = 0.9282$ ,  $P < 0.01$  for ciprofloxacin).

1  
2  
3 The incidence rate of MRSA was positively correlated with the consumption of  
4 FQs( $r=0.9450$ ,  $P < 0.01$  for levofloxacin and  $r=0.8883$ ,  $P < 0.05$  for ciprofloxacin). However,  
5  
6  
7 we found that the incidence rate of MRSA was negatively correlated with the consumption of  
8  
9  
10 imipenem/cilastatin ( $r= - 0.9611$ ,  $P < 0.01$ ) (Table 6).  
11  
12  
13

## 14 15 **DISCUSSION**

16  
17 The global mortality attributable to AMR is estimated to reach 10 million annually by  
18  
19  
20 2050, which would make it one of the leading causes of death, with an economic impact of  
21  
22 up to 100 trillion US dollars (USD).<sup>16</sup>Therefore, many countries worldwide have  
23  
24 implemented AMS, with many positive effects in the rational use of antibiotics and health  
25  
26 care cost savings.<sup>17-21</sup>  
27  
28

29 The implementation of AMS in our hospital is managed by clinical pharmacists and  
30  
31 supported by the DTC, while multiple sectors participate in it. AMS includes a multifaceted  
32  
33 approach to combat the spread of AMR. Except the regular management strategy (such as  
34  
35 multidisciplinary consultation, nosocomial infection control, prescription prospective audit,  
36  
37 prescription evaluation and feedback, publicity and education, etc), our hospital established  
38  
39 the reward and punishment mechanism aiming to arouse the doctor's attention to the rational  
40  
41 use of antibiotics, which is slightly different from the existing intervention model and is  
42  
43 unique among the published studies of AMS, but it reflects the current situation of some  
44  
45 Chinese hospitals. After many years of AMS, the proportion of antibiotic prescriptions  
46  
47 decreased to 13.21% among outpatients and 34.65% among inpatients. The intensity of  
48  
49 antibiotic consumption was reduced to 37.38 DDD/100 bed-days. These outcomes are similar  
50  
51 to the study by Bao *et al.*<sup>15</sup>Regarding antibiotic prophylaxis in type I incision operations, the  
52  
53 proportion of antibiotic prophylaxis decreased to 18.93% and the proportion of rational  
54  
55 timing of the initial dose increased to 96.74%. Only the proportion of rational duration of  
56  
57  
58  
59  
60

1  
2  
3 antibiotic prophylaxis (42.63%) did not reach the national standard, for the following reasons.  
4  
5 First, coronary artery bypass graft (CABG) surgery belongs to type I incision operations,  
6  
7 according to the Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,<sup>22</sup>the  
8  
9 duration of prophylaxis for cardiothoracic procedures is up to 48 hours, with no supporting  
10  
11 evidence. Chinese Guidelines suggest prophylactic duration be no more than 48 hours. But  
12  
13 CABG involves important viscera, in which the consequences of infection would be severe.  
14  
15 Therefore, doctors hesitate to stop antibiotics within 48 hours after surgery. Second, in  
16  
17 orthopedic surgeries, such as open reduction and plate or screw internal fixation of fractures,  
18  
19 in consideration of implants doctors also hesitate to stop antibiotics within 24 hours after  
20  
21 surgery. Third, the difficult doctor-patient relationships in China make physicians hesitant  
22  
23 about premature discontinuation of antibiotics.  
24  
25  
26  
27

28  
29 The aim of AMS is to limit the prevalence of AMR. The results showed that with  
30  
31 decreased intensity of FQ consumption, the resistance rates of *E. coli* and *P.aeruginosa* to  
32  
33 FQs and incidence rate of MRSA showed decreasing trends, and they were positively  
34  
35 correlated. This implied that controlling the use of FQs might limit the prevalence of AMR as  
36  
37 well as limit the emergence of MRSA; the latter is consistent with previous studies.<sup>23,24</sup>Other  
38  
39 studies<sup>25-28</sup>have reported that a reduction in second/third-generation cephalosporins and  
40  
41 clindamycin contributed to a reduction in both incidence rate of MRSA and prevalence  
42  
43 density of MRSA bacteremia. In our study, we also found that the incidence rate of MRSA  
44  
45 was negatively correlated with imipenem/cilastatin use, which was difficult to explain. To our  
46  
47 knowledge, few studies have obtained results similar to ours. Lai *et al.* reported<sup>29</sup>a significant  
48  
49 correlation between increased use of linezolid and teicoplanin and decreased prevalence of  
50  
51 MRSA. Therefore, we theorize that the reduced use of non-special grade antibiotics (such as  
52  
53 FQs and others) leads to a compensatory increased use of carbapenems; however, this  
54  
55 negative correlation requires further exploration. In addition, we found the resistance rate of  
56  
57  
58  
59  
60

1  
2  
3 *E. coli* and *K.pneumoniae* to carbapenems showed an increasing trend, meaning that  
4 carbapenem-resistant Enterobacteriaceae (CRE) could pose a serious threat. On March 3,  
5  
6  
7  
8 2017, the NHFPC issued a Notice Regarding Further Reinforcement in Management of  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

*E. coli* and *K.pneumoniae* to carbapenems showed an increasing trend, meaning that carbapenem-resistant Enterobacteriaceae (CRE) could pose a serious threat. On March 3, 2017, the NHFPC issued a Notice Regarding Further Reinforcement in Management of Clinical Application of Antibacterial to Control Bacteria Resistance, which required medical institutions to gather, archive, and analyze patient information with respect to the use of carbapenems, to help control the prevalence of CRE.<sup>30</sup>

CHINET surveillance of AMR in China reported the resistance trends from 2005 to 2014, using data from 19 hospitals.<sup>31</sup>In our hospital, the resistance rates of *E. coli*, *K.pneumoniae*, and *P.aeruginosa* to imipenem/cilastatin and meropenem in 2014 (0.4% and 0.9%, 4.8% and 4.1%, 16.5% and 12.9%, respectively) were significantly lower than those reported by CHINET (0.9% and 1.0%, 10.5% and 13.4%, 26.6% and 24.3%, respectively). This proved that AMS in our hospital played an important role in control of AMR.

Some limitations of this study should be noted. First, this was a retrospective observational study without simultaneous control group, the bias couldn't be well controlled, it was less convincing than a prospective, controlled study design. So the favorable results obtained can not be attributed solely to the pharmacist intervention, which were affected by many factors. Second, because AMS has been ongoing for many years, several different clinical pharmacists have successively participated in the evaluation of prophylactic antibiotic use; therefore, the evaluation results might be affected slightly by individual differences.

## CONCLUSION

This study demonstrated that AMS in our hospital could reduce and optimize antibiotic use, declining bacterial resistance to FQs was associated with its reduced consumption. Clinical pharmacists played an important role in improving the rational use of antibiotics, however, hospital infection prevention and control measures, national policy guidance all

1  
2  
3 contributed to it. The findings of our study indicate some directions to pursue in controlling  
4 the prevalence of CRE and MRSA. AMR is rising worldwide, so continual effort regarding  
5 AMS is critical not only in large hospitals but also in primary or community hospitals.  
6  
7  
8  
9  
10

11  
12 **Acknowledgments** The authors thank Guosheng Feng and Zhaohui Tong, directors of  
13 Beijing Chaoyang Hospital, for supporting and promoting antimicrobial stewardship work.  
14 We also thank Analisa Avila, ELS, of Liwen Bianji, Edanz Group China  
15 ([www.liwenbianji.cn/ac](http://www.liwenbianji.cn/ac)), for editing the English text of a draft of this manuscript.  
16  
17  
18  
19  
20

21 **Contributors** LHL was the leader of AMS and responsible for supervising the work, work  
22 plan, and manuscript review. HGW was responsible for carrying out AMS and collecting,  
23 analyzing, and reporting data; she wrote this manuscript and made some amendments after  
24 review. HW was responsible for statistical analysis and wrote the analysis method in the  
25 manuscript. XJY, HZ, BYL, GC, ZKY, YW, XLC, YYZ, RZ, ZHW, HY were all involved in  
26 the different aspects of data collection. PW and CXY provided the bacterial resistance data.  
27 All authors were involved in data verification.  
28  
29  
30  
31  
32  
33  
34  
35  
36

37 **Funding** There is no specific funding for this study.

38  
39 **Competing interests** None declared.

40  
41 **Patient consent** Not required.

42  
43 **Ethics approval** Beijing Chaoyang Hospital Ethics Committee.  
44

45  
46 **Data sharing statement** No additional unpublished data are available.  
47

## 48 49 REFERENCES

- 50  
51 1. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. *Pathog*  
52 *Glob Health* 2015;109(7):309-18.  
53  
54 2. Xiao YH, Giske CG, Wei ZQ, *et al.* Epidemiology and characteristics of antimicrobial resistance in China. *Drug*  
55 *Resist Updat* 2011;14(4-5):236-50.  
56  
57 3. World Health Organization. Global strategy for containment of antimicrobial resistance.  
58  
59  
60



- 2001(WHO/CDS/CSR/DRS/2001.2).
4. National Health and Family Planning Commission of the People's Republic of China. Notice regarding National Special Measure Scheme on Clinical Use of Antibiotics[in Chinese].2011.<http://www.nhfpc.gov.cn/zwgkzt/wsbysj/201104/51376.shtml>
  5. Zhang HX, Li X, Huo HQ, *et al.* Pharmacist interventions for prophylactic antibiotic use in urological inpatients undergoing clean or clean-contaminated operations in a Chinese hospital. *PLoS One* 2014;9(2):e88971.
  6. Davey P, Brown E, Charani E, *et al.* Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev* 2013;(4):CD003543.
  7. Ma X, Xie J, Yang Y, *et al.* Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant organism isolates in critically ill patients: a pre-post study from a single center. *BMC Infect Dis* 2016;16(1):704.
  8. Xu J, Duan X, Wu H, *et al.* Surveillance and correlation of antimicrobial usage and resistance of *Pseudomonas aeruginosa*: a hospital population-based study. *PLoS One* 2013;8(11):e78604.
  9. Horikoshi Y, Suwa J, Higuchi H, *et al.* Sustained pediatric antimicrobial stewardship program with consultation to infectious diseases reduced carbapenem resistance and infection-related mortality. *Int J Infect Dis* 2017;64:69-73.
  10. Wushouer H, Zhang ZX, Wang JH, *et al.* Trends and relationship between antimicrobial resistance and antibiotic use in Xinjiang Uyghur Autonomous Region, China: Based on a 3 year surveillance data, 2014-2016. *J Infect Public Health* 2018;11(3):339-346.
  11. Cusini A, Herren D, Bütikofer L, *et al.* Intra-hospital differences in antibiotic use correlate with antimicrobial resistance rate in *Escherichia coli* and *Klebsiella pneumoniae*: a retrospective observational study. *Antimicrob Resist Infect Control* 2018;7:89.
  12. Notice Regarding Implementing Stewardship of Antibacterial Use in Clinic in April 2014 [in Chinese].2014.<http://www.nhfpc.gov.cn/yzygj/s3593/201404/49973560ddde4293a489b158081d777c.shtml>
  13. National Health and Family Planning Commission of the People's Republic of China. Regulations on Clinical Applications of Antibiotics [in Chinese].2012.<http://www.nhfpc.gov.cn/yzygj/s3593/201205/e5efd852b86c4afa8b09a0e58e09e10e.shtml>

- 1  
2  
3 14. World Health Organization. Collaborating Center for Drug Statistics Methodology: Guidelines for ATC  
4 classification and DDD assignment  
5  
6  
7 2017. [http://www.who.cco/filearchive/publications/2017\\_guidelines\\_webpdf](http://www.who.cco/filearchive/publications/2017_guidelines_webpdf).  
8
- 9 15. Bao L, Peng R, Wang Y, *et al*. Significant reduction of antibiotic consumption and patients' costs after an  
10 action plan in China. 2010-2014. *PLoS One* 2015;10(3):e0118868.  
11
- 12 16. Alawi MM, Darwesh BM. A stepwise introduction of a successful antimicrobial stewardship program.  
13 Experience from a tertiary care university hospital in Western, Saudi Arabia. *Saudi Med J*  
14 2016;37(12):1350-1358.  
15
- 16 17. Song P, Li W, Zhou Q. An outpatient antibacterial stewardship intervention during the journey to JCI  
17 accreditation. *BMC Pharmacol Toxicol* 2014;15:8.  
18
- 19 18. Dinh A, Duran C, Davido B, *et al*. Impact of an antimicrobial stewardship program to optimize antimicrobial  
20 use for outpatients at emergency department. *J Hosp Infect* 2017 Jul 8. pii: S0195-6701(17)30387-0.  
21
- 22 19. Doernberg SB, Dudas V, Trivedi KK. Implementation of an antimicrobial stewardship program targeting  
23 residents with urinary tract infections in three community long-term care facilities: a quasi-experimental  
24 study using time-series analysis. *Antimicrob Resist Infect Control* 2015;4:54.  
25
- 26 20. Jenkins TC, Knepper BC, Shihadeh K, *et al*. Long-term outcomes of an antimicrobial stewardship program  
27 implemented in a hospital with low baseline antibiotic use. *Infect Control Hosp Epidemiol*  
28 2015;36(6):664-72.  
29
- 30 21. Li Z, Cheng B, Zhang K, *et al*. Pharmacist-driven antimicrobial stewardship in intensive care units in East  
31 China: A multicenter prospective cohort study. *Am J Infect Control* 2017;45(9):983-9.  
32
- 33 22. Bratzler DW, Dellinger EP, Olsen KM, *et al*. Clinical practice guidelines for antimicrobial prophylaxis in  
34 surgery. *Am J Health Syst Pharm* 2013;70(3):195-283.  
35
- 36 23. Charbonneau P, Parienti JJ, Thibon P, *et al*. Fluoroquinolone use and methicillin-resistant *Staphylococcus*  
37 aureus isolation rates in hospitalized patients: a quasi experimental study. *Clin Infect Dis*  
38 2006;42(6):778-84.  
39
- 40 24. Weber SG, Gold HS, Hooper DC, *et al*. Fluoroquinolones and the risk for methicillin-resistant *Staphylococcus*  
41 aureus in hospitalized patients. *Emerg Infect Dis* 2003;9(11):1415-22.  
42
- 43 25. Aldeyab MA, Scott MG, Kearney MP, *et al*. Impact of an enhanced antibiotic stewardship on reducing  
44 methicillin-resistant *Staphylococcus aureus* in primary and secondary healthcare settings. *Epidemiol Infect*  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 2014;142(3):494-500.
26. Lawes T, Edwards B, Lopez-Lozano JM, *et al.* Trends in Staphylococcus aureus bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006-2010: retrospective cohort study and time-series intervention analysis. *BMJ Open* 2012;2(3).
27. Tacconelli E, De Angelis G, Cataldo MA, *et al.* Does antibiotic exposure increase the risk of methicillin-resistant Staphylococcus aureus (MRSA) isolation? A systematic review and meta-analysis. *J Antimicrob Chemother* 2008;61(1):26-38.
28. Borde JP, Kaier K, Steib-Bauert M, *et al.* Feasibility and impact of an intensified antibiotic stewardship programme targeting cephalosporin and fluoroquinolone use in a tertiary care university medical center. *BMC Infect Dis* 2014;14:201.
29. Lai CC, Chu CC, Cheng A, *et al.* Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010. *J Microbiol Immunol Infect* 2015;48(4):431-6.
30. National Health and Family Planning Commission ( NHFPC ) of the People's Republic of China. Notice regarding Further reinforcement the Management of Clinical Application of Antibacterial to Control Bacteria Resistant [in Chinese].2017. <http://www.nhfpc.gov.cn/yzygj/s7659/201703/d2f580480cef4ab1b976542b550f36cf.shtml>.
31. Hu FP, Guo Y, Zhu DM, *et al.* Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. *Clin Microbiol Infect* 2016;22 Suppl 1:S9-14.

### Figure legends:

#### Figure 1. Changes in proportion of antibiotic prescriptions and intensity of consumption.

Time series curves of each monthly value of antibiotic prescribing proportions, plotted for outpatients (A) and inpatients (C). Each monthly value of intensity of antibiotic consumption was plotted for inpatients (E). The Bonferroni test was conducted to compare these data in

1  
2  
3 three stages, for antibiotic prescribing proportion among outpatients (B) and inpatients (D),  
4 and intensity of antibiotic consumption (F). Stage 1, Stage 2, and Stage 3 on the x-axis  
5  
6 represent the baseline phase, intervention phase, and stability phase, respectively.  
7  
8  
9

10 **Figure 2. Changes in antibiotic prophylaxis in type I incision operations.**

11  
12 Time series curves of each monthly value of antibiotic prophylaxis were plotted for  
13 proportion of prophylaxis (A), proportion of rational timing (C), and proportion of rational  
14 duration (E). These data in three stages were compared by Bonferroni test (B, D, and F).  
15  
16 Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase,  
17 and stability phase, respectively.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1. Changes in proportion of antibiotic prescriptions and intensity of consumption.

Time series curves of each monthly value of antibiotic prescribing proportions, plotted for outpatients (A) and inpatients (C). Each monthly value of intensity of antibiotic consumption was plotted for inpatients (E).

The Bonferroni test was conducted to compare these data in three stages, for antibiotic prescribing proportion among outpatients (B) and inpatients (D), and intensity of antibiotic consumption (F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.

388x207mm (144 x 144 DPI)




Figure 2. Changes in antibiotic prophylaxis in type I incision operations. Time series curves of each monthly value of antibiotic prophylaxis were plotted for proportion of prophylaxis (A), proportion of rational timing (C), and proportion of rational duration (E). These data in three stages were compared by Bonferroni test (B, D, and F). Stage 1, Stage 2, and Stage 3 on the x-axis represent the baseline phase, intervention phase, and stability phase, respectively.

546x292mm (144 x 144 DPI)

## Supplementary materials

**Table S1** Trend changes in incidence rate of methicillin-resistant *Staphylococcus aureus* from 2011 to 2016

	By year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	<i>P</i>
<b>Incidence rate (%)</b>	68.0	60.3	58.3	49.8	51.5	37.5	Decreasing	-5.2565	0.0007

**Table S2** Usage trend changes of carbapenems and fluoroquinolones from 2011 to 2016

Anti biotic	Anti biotic consumption (DDD/100 bed-days) by year						Time series analysis		
	2011	2012	2013	2014	2015	2016	Trend	$\beta$	<i>P</i>
Imipenem/cilastatin	0.59	0.71	0.79	1.17	1.16	1.36	Increasing	0.1599	0.0013
Meropenem	0.86	0.34	0.29	0.38	0.66	0.69	Stable	-0.0116	0.9193
Levofloxacin	11.18	9.70	10.64	7.74	7.71	6.35	Decreasing	-0.9292	0.0033
Ciprofloxacin	6.17	4.12	2.49	0.91	0.66	0.45	Decreasing	-1.1811	0.0461

DDD, defined daily dose.

## STROBE Statement—checklist of items that should be included in reports of observational studies

**Our research met all the items of STROBE statement.**

	Item No	Recommendation	Page number
<b>Title and abstract</b>	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1,2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2,3
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-5
Objectives	3	State specific objectives, including any prespecified hypotheses	3-5
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	2,4,5,8,9
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	Not Applicable for this study.
		<i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls	
		<i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed	
		<i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5-10
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	8-10
Bias	9	Describe any efforts to address potential sources of bias	9-10
Study size	10	Explain how the study size was arrived at	1,2
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	8-10
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8-10
		(b) Describe any methods used to examine subgroups and interactions	8-10
		(c) Explain how missing data were addressed	None
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	Not Applicable for this study
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	
<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy			
	(e) Describe any sensitivity analyses	8-10	



Continued on next page

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

<b>Results</b>		<b>Page number</b>	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	2-3
		(b) Give reasons for non-participation at each stage	Applicable for this study
		(c) Consider use of a flow diagram	Applicable for this study
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Applicable for this study
		(b) Indicate number of participants with missing data for each variable of interest	
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Applicable for this study
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Applicable for this study
		(b) Report category boundaries when continuous variables were categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	10-12
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives	19-21
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	4,22
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	18-22
Generalisability	21	Discuss the generalisability (external validity) of the study results	20-22
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	None

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).